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The host antiviral innate immunity mainly relies on host pattern recognition 
receptors (PRR) and downstream interferon (IFN) signaling. Host PRR for RNA 
viruses include Toll-like receptors (TLR) and Retinoic acid-inducible gene I (RIG-I) 
like receptors (RLR). Activation of both TLR and RLR pathways can eventually lead 
to the secretion of type I IFNs, which can modulate both innate and adaptive immune 
responses against viral pathogens, including hepatitis E virus (HEV). HEV causes 
acute hepatitis in humans and has been responsible for several outbreaks of hepatitis 
across the world. Currently, no commercial vaccine is available for the prevention of 
HEV infection in any country except China. HEV biology and pathogenesis as well as 
its responses to host innate immunity are poorly understood, though other hepatitis 
viruses, including the hepatitis A, B and C viruses, have been much better studied. In 
  
this study, how HEV interferes with IFN induction and IFN-activated signaling had 
been examined. Results showed that the protein encoded by HEV ORF1 can inhibit 
type I IFN synthesis and downstream JAK/STAT signaling pathway. However, the 
HEV ORF3 product is able to enhance RIG-I-mediated signaling to a certain extent. 
These data suggest that HEV proteins interfere with the host innate immune response 
and may exert the diverse roles depending on the stage and/or context of infection. 
These studies contribute to a better understanding of HEV pathogenesis and may 
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Chapter 1: Hepatitis E Virus 
Introduction 
Hepatitis E virus (HEV) causes acute hepatitis in humans and has been 
responsible for several large outbreaks of hepatitis across the world. It has been classified 
as the sole member of the genus Hepevirus, the family Hepeviridae (74). Currently, there 
is no commercial vaccine available for prevention of this infectious disease in any 
country except for China. HEV is a fecal-oral transmitted viral pathogen that causes acute 
hepatitis with a mortality rate from 0.5 to 3% in young adults and up to 30% in pregnant 
women in their third trimester of gestation (139). It has been estimated that one third of 
total population in the world have been infected by HEV on the basis of seroprevalence. 
However, for a long time, HEV infection was thought to be a public health problem only 
for the developing countries. Hepatitis E is now frequently recognized in industrialized 
countries, where it was not thought to be endemic (76, 145, 185, 252, 337, 348, 430). 
Moreover, HEV is also a zoonotic agent and isolation of HEV from the pig, chicken, 
mongoose, rabbit, rat, ferret, bat, fish and deer has been reported (105, 202, 246). It is 
thought that transmission of HEV from animal reservoirs to humans is the major cause of 
sporadic cases of hepatitis E in the industrialized countries. In this chapter, the molecular 
virology, cell culture system, pathogenesis, epidemiology, treatment and vaccine of HEV 
are discussed in detail.  
HEV Virology 
Originally, hepatitis E was classified as enterically transmitted non-A, non-B 





but the prospective causative agent was unknown (321). Although earlier research 
implied an RNA virus as the potential pathogen for the ET-NANBH, direct evidence 
came from the Reyes group. By using infectious bile to construct a cDNA library, they 
identified a portion of a highly conserved RNA-dependent RNA-polymerase (RdRp) 
motif, which is present in all RNA viruses (320). They designated this new virus as the 
hepatitis E virus, which was responsible for the outbreak of ET-NANBH.  
The complete sequence of the HEV genome came out one year later (393). 
Computer based analysis of the sequencing data indicated it has a 7.2 kb single-stranded 
positive-sense RNA genome, which is capped and poly-adenylated. It contains three 
partially overlapped open reading frames (ORFs) with an order of sequences encoding 
non-structural proteins, followed by sequences encoding structural proteins (393, 401) 
[Fig.1.1]. HEV ORF1 encodes a polyprotein including non-structural proteins of HEV. 
ORF2 encodes the capsid protein, which is the major structural protein of the HEV virion. 
ORF3 encodes a small multifunctional protein with a molecular weight of 13 kDa (vp13). 
There are also short untranslated regions (UTRs) in both the 5′- and 3′- end of the 
genome.  
 
   
 






The ORF1 of HEV can be translated directly from its genomic RNA, while ORF2 
and ORF3 can be translated only from sub-genomic RNAs (99). In an earlier report, three 
RNA species were detected in the liver tissue of experimentally infected macaques, with 
sizes of 7.2, 3.7 and 2 kb (393). The 3.7 and 2 kb RNA species were considered to be 
sub-genomic RNAs for ORF2 and ORF3 translation, respectively. However, a later study 
in Huh7 cells only identified one capped 2.2 kb sub-genomic RNA, which was 
considered to be a bicistronic mRNA for translation of both ORF2 and ORF3 (99). 
Transcription of this sub-genomic RNA initiates at nucleotide position 5122 in the Sar55 
strain, which is located downstream of the first two methionine codons of the earlier 
presumed ORF3. The same conclusion was drawn from another in vitro assay of type III 
HEV infection in RLC/PRF/5 cells (135). 
HEV was initially classified as a member of the Caliciviridae family. However, 
sequence comparison of the HEV ORF1 with corresponding ORFs from other viruses 
indicated no homology with Caliciviruses, or other picorna-like viruses. On the other 
hand, there is limited but significant homology with the alphavirus-like superfamily of 
RNA viruses, specifically the rubella virus (30). Consequently, HEV was reclassified as 
the only member of the genus Hepevirus (30, 74). 
Genotypes of Hepatitis E viruses 
HEV strains are highly diverse and heterogenic. Classification of HEV strains is 
under transition due to the different criteria used (372). Early classification was based on 
partial genomic sequences, i.e. strains with nucleotide variations differing by >20% in 





analysis of the complete genome and sub-genome regions has classified HEV into at least 
four major genotypes with several subtypes in each (222). HEV genotype I with the 
prototype Sar55 strain is the most conserved among the four genotypes and contains five 
subtypes. The genotype II sequences are limited and can be divided into two subtypes. 
Genotype III and IV strains are highly diverse and there are ten and seven subtypes, 
respectively (222). Both HEV genotypes I and II are restricted to humans with no animal 
reservoirs, whereas genotypes III and IV are zoonotic with an expanded host range (7, 
245). However, as new HEV isolates from rabbit, rats, ferret, bats and wild boar have 
been reported, there is concern as to whether these new isolates should be listed as a new 
genotype or subtype (64, 90, 144, 309, 386, 456).  
There have also been HEV-like viruses isolated from avian species called avian 
HEV (105, 132). Avian HEV shares less than 50% nucleotide identity with mammalian 
HEV and has been proposed as a new genus within the family Hepeviridae (International 
Committee for the Taxonomy of Viruses; Ninth Report) (132, 414). However, the 
common antigen epitopes in the capsid protein are shared among mammalian HEV and 
avian HEV (104). A more recent study further classified HEV strains into six genotypes 
with two additional genotypes from wild boar (372). Moreover, although it is very rare, 
intra- and inter genotypic recombination of HEV has been reported and is believed to 
contribute to the diversity of this virus (423). 
For the traditional four genotypes of HEV, there are differences in their 
geographic distributions. Genotype I HEV mainly includes strains from Asia and Africa 





from Africa. However, genotypes III, including human and swine HEV, are mainly found 





Viral Proteins of HEV 
ORF1 polyprotein   
ORF1 of HEV is the largest ORF in the HEV genome with 5082 bp in length 
according to the prototype Sar55 strain (75, 401). It starts at the 5’ end of the genome 
after a 25 bp non-coding region and can be translated directly from the HEV genome. 
ORF1 encodes a 1693 amino acid (aa) polyprotein, which is necessary for viral 
replication and protein processing. Bioinformatic analysis of the ORF1 sequence has 
revealed that it is highly related to the group of Rubi-like viruses including Rubivirus, 
Betatetravirus, Benyvirus, Omegatetravirus, Sclerotinia sclerotiorum debilitation-
associated virus and cutthroat trout virus (26, 178, 214). The analysis also indicated eight 
putative functional domains according to the homology of already known functional 
domains from other viruses (179) [Fig.1.2]. These functional domains can be listed as 
follows from the protein’s N terminus: methyltransferase domain (Met), Y domain (Y), 
papain-like cysteine protease (PCP), hypervariable region (HVR), proline-rich region 
(Pro), X domain, helicase domain (Hel) and RNA-dependent RNA polymerase domain 
(RdRp). In recent publications, the proline-rich region has been incorporated into the 
hypervariable region.  
The current data are controversial about whether the HEV ORF1 product 
functions as a single polyprotein or needs to be further processed into smaller units by 
viral or cellular proteases (17, 289, 329, 357, 381). An earlier study by the Frey group 
using a vaccinia-derived expression system demonstrated that the ORF1 polyprotein can 
be cleaved by the PCP within it (329). However, more than ten years later, a publication 





cells, which contradicts their previous observation (381). In another report by Perttila et 
al., although in vitro translation of full-length pORF1 yielded smaller quantities of two 
fragments, these fragments were not observed in pulse–chase studies in human cells, and 
their production was not dependent on the predicted protease domain in pORF1(289). 
Furthermore, in E. coli and a cell-free system based on HepG2 cells, ORF1 was 





However, other studies demonstrated contrasting results. In one study, the ORF1 
product expressed in insect cells by a baculovirus system could be processed into smaller 
fragments correlated with proposed functional domains, and this type of processing could 
be inhibited by E-64d, a cell-permeable cysteine protease inhibitor (357). In a more 
detailed study, transfection of HepG2 cells with in vitro transcribed RNA from HEV 
cDNA produced cleaved products with sizes of 35, 38 and 36 kDa for the Met, Hel and 
RdRp domains, respectively (279). Another study focusing on the analysis of the ORF1 
functional domains also observed proteolytic processing of the HEV ORF1 fragment in 
insect cells (227). A recent publication reported that the refolded PCP domain expressed 
in E. coli is able to process ORF1 protein in vitro (277). Moreover, based on an HEV-
Sar55 replicon system in S10-3 cells (a subclone of Huh7 cells with improved HEV 
replication) (99), it has been demonstrated that the putative “catalytic” aa residues in the 
Fig. 1.2 Schematic illustration of ORF1 product. 
Met: Methyltransferase domain; Y: Y domain; PCP: papain-like cysteine protease; HPX: 
hypervariable region, proline-rich domain and X-domain; Hel: helicase; RdRp: RNA-dependent 







ORF1 protease domain are indispensable during HEV replication, as well as the putative 
X-domain “protease-substrate” residues (282). Overexpression of ORF1 from HEV Sar55 
strain in S10-3 cells also resulted in cleaved products that were barely visible (282).  
Thus, although there is no solid data to support a conclusion on the processing of 
the HEV ORF1 polyprotein, majority of the data available so far are in favor of the 
polyprotein proteolysis, which indicates that HEV ORF1 can be processed into smaller 
units. Additionally, some studies have analyzed the functions of the putative domains. 
Met domain 
The Met domain is the first functional domain of the ORF1 polyprotein. As 
evidence has indicated that the HEV genome is capped and that the capping is crucial for 
its infectivity, a viral-specific methyltransferase is expected (75, 450). Based on 
bioinformatic analysis, aa residues 60-240 could be the putative methyltransferase (179). 
The HEV Met domain shows high similarity to that of Tricornaviruses, which belong to 
the alpha-like supergroup of RNA viruses (414). Members of this virus superfamily code 
a unique methyltransferase with four conserved motifs. There are an invariant His residue, 
an AspXXArg signature and an invariant Tyr residue in motifs I, II, and IV of 
methyltransferase, respectively (333). Expression of HEV ORF1 cDNA (aa residue 1-979) 
in insect cells yields a 110 kDa protein (P110), along with a 80 kDa protein which is 
believed as the proteolytically processed product from P110 (227). In vitro assays have 
confirmed that P110 possesses guanine-7-methyltransferase as well as guanylyl 






The second functional domain following methyltransferase is the Y domain. It 
starts from aa residue 216 and ends at aa 442, and is highly similar to that of the rubella 
virus (179). Currently, no information is available for the function of this Y domain in 
either HEV or the rubella virus.  
PCP domain 
Downstream of the Y domain, there is a putative papain-like cysteine protease 
(PCP) domain. Just as the Y domain, the PCP domain demonstrates moderate similarity 
with the protease domain in the rubella virus (179). In the rubella virus, the PCP domain 
is responsible for the proteolytic processing of its non-structural protein (NSP) (232). 
Mutation of the catalytic residue within the PCP (Cys1151) abolishes its protease activity 
and results in inhibition of the NSP processing. It is also involved in trans and cis 
cleavage of the rubella virus NSP (208). However, regarding the function of the HEV 
PCP domain, the current data are incomplete and controversial.  
In the vaccinia-mediated ORF1 expression system, mutation of the putative 
catalytic core (Cys483) of HEV PCP had no effect on proteolytic processing of the ORF1 
product (329). Another putative catalytic site of His590 in PCP is not conserved among 
different HEV strains. Later studies showed controversial data for the processing of the 
HEV ORF1 product (17, 329, 357, 381), which leads to the speculation as to whether 
HEV PCP is a real cysteine protease. Recently, Parvez demonstrated that the mutation of 
six cystine residues (C457, C459, C471, C472, C481, C483) and three histidine residues 
(H443, H497, H590) in the PCP domain completely abolished HEV RNA replication in a 





residues, C483 and H590 had been previously predicted as putative catalytic residues in 
the PCP domain (282). Furthermore, an Indian group demonstrated that the PCP domain 
expressed in the E. coli C43 strain (a strain resistant to toxic protein expression) 
possesses protease activity (277). The recombinant protein was shown to cleave both in 
vitro translated HEV ORF1 and ORF2 products. Protease inhibitor assays further 
indicated the HEV PCP domain is a chymotrypsin-like protease (277). This latter 
evidence indicates that HEV PCP could be a real protease responsible for HEV ORF1 
polyprotein processing. 
In recent years, the connection between ubiquitination and innate immunity 
signaling has been demonstrated (216, 231, 448), and the antiviral function of some 
ubiquitin-like molecules, such as ISG15 and SUMO, has been described (216). Evidence 
from other studies indicate that viral coded cysteine proteases possess deubiquitinase 
activity to inhibit host innate immunity, such as arterivirus papain-like protease 2 (415) 
and PCP from porcine reproductive and respiratory syndrome virus (199, 380). As a 
result, similar research was performed on the HEV PCP domain, which suggests that 
HEV PCP could act as an antagonist to ISG15 function to inhibit host innate immunity 
when expressed together with Met as the Met-PCP protein (157).  
HVR domain 
Between the PCP domain and the X domain, there are a hypervariable region 
(HVR) and a proline-rich region (Pro). Those two regions were first named together as 
the hypervariable region due to the extreme divergence between nt2011 to nt2325 
(corresponding to aa 662 to 766) when comparing the HEV prototype Sar55 with two 





proline-rich region, which could be found in rubella virus as well. It was also considered 
to serve as a hinge between the X domain and its upstream domains because multiple 
prolines in a protein or peptide may result in an unstable tertiary structure (63, 67, 179, 
400). The length and sequence of HVR and Pro is highly variable among different HEV 
strains and usually need to be excluded for phylogenetic analysis (302, 372). Currently, 
there is some confusion regarding the designation of those two regions. Some of the 
recent publications have named the aa 712 to 778 region as the hypervariable domain, 
which originally referred to proline-rich region and left out the immediately upstream 
domain (aa 592 to 711) (302, 303), while others still name the aa 712 to 778 domain as 
the proline-rich region (305). Current research mainly focuses on the Pro domain and 
pays less attention to the upstream HVR domain. As a result, the function of HVR is 
unknown. However, data gained from the rubella virus shows that deleting part of the 
HVR domain along with part of the Pro domain results in a mutant unable to replicate 
(410). 
Pro domain 
The Pro domain is considered as an intrinsically disordered region (IDR) with 
flexibility for insertion and deletion (305, 306). Data from its counterpart in the rubella 
virus indicates that this region is not required for viral replication (410). As expected, 
deletion and mutation of this region in HEV indicates that it is not required for viral 
replication and infectivity, but it plays a role in replication efficiency in vitro (302, 303). 
It was also demonstrated that the Pro domain is interchangeable between genotypes with 
genotype-specific differences and is affected by viral replication (303). More 





derived from an HIV patient with chronic HEV infection, demonstrated an insertion of a 
174 bp gene fragment of human ribosomal protein S17 in the Pro region (369). This 
recombinant virus was adapted in cell culture and was permissible for cells from different 
species. It was speculated that insertion of the S17 fragment into the viral genome 
occurred in the host but was selected in cultured cells. This speculation needs further 
verification as direct detection of the inserted fragment from the host sample was not 
successful. Experimental insertion of the S17 fragment into the Pro domain of the 
prototype Sar55 strain also generated a viable chimeric virus and further demonstrated 
that this region could tolerate sustainable changes (369).  
Although the Pro domain was considered a highly diverse region that is 
intrinsically disordered regions (IDR), some motifs are found in the region. Based on 
computer analysis and predication with comparison of other IDRs, Purdy et al. identified 
several linear motifs (LMS), including two protease cleavage sites, three ligand binding 
sites and two kinase phosphorylation sites across all four genotypes and the HEV strain 
isolated from a Japanese wild boar (306). The putative protein-protein interactions of the 
Pro domain were proposed in the same report as well, but need experimental verification. 
Nevertheless, this report provides some useful insight into disorder-to-order state 
transitions about the Pro domain. In a recent study, alignment of the Pro domain from 
different genotypes indicated the sequence is more conserved in genotypes I and II rather 
than genotypes III and IV (305). Adaption of a wider host range for genotypes III and IV 
was a possible reason. The authors also assessed the diversity of the Pro domain due to 
the higher rate of substitutions at the first and second codon positions, leading to a shift in 





phenylalanine, tryptophan and tyrosine. This pattern matches the aa usage in proline-rich 
IDRs (305). Furthermore, it is probable that all zoonotic HEV isolates share a common 
ancestor for the Pro domain, and the C-terminus of this domain could tolerate more 
mutations than the N-terminus. HEV evolution has favored the formation of IDR 
structures in the Pro domain (305). Recently, the heterogeneity of the Pro and X domains 
is implicated in HEV persistence, which was revealed in an investigation into the 
association between the genetic heterogeneity of HEV quasispecies in ORF1 and the 
outcome of infection in solid-organ transplant patients (198). 
X Domain 
The X domain is located immediately downstream of the Pro domain. In HEV, it 
was first identified as a domain with unknown function, which commonly flanks the PCP 
domain in the rubella virus, alpha virus and coronavirus (95, 179). It has now been given 
a new name, macro domain, due to its homology shared with non-histone domain of the 
histone macroH2A. It has been identified in a variety of bacterial, archaeal and 
eukaryotic organisms (286, 287).  
Earlier studies into the human macro domain indicated that it is enriched in 
inactive mammalian X chromosomes, suggesting a role in gene silencing and inactivation 
(51). The in vitro assays have shown that the macro domain inhibits transcription, and 
this inhibition was further confirmed by binding of the macro domain to the transcription 
factor NF-κB (16, 288). Crystal structure analysis also identified a DNA binding motif in 
the macro domain, suggesting that it might interact with nucleic acids (12). A 
biochemical functional analysis indicated that the macro domain is involved in the 





splicing (233). Furthermore, the macro domain had been found in association with 
proteins involved in poly(ADP-ribose) polymerization, ADP-ribosylation and ATP-
dependent chromatin remodeling (6).  
Information about the viral macro domain is limited. ADP-ribose 1"-phosphatase 
activities have been demonstrated in macro domains from three coronaviruses (233, 307, 
308, 338). Crystal structure analysis and in vitro assays on the macro domain of the 
SARS virus indicate that the viral macro domain has relatively poor ADP-ribose 1"-
phosphohydrolase activity, but can bind free ADP-ribose and poly(ADP-ribose) 
efficiently (69). In another report, the viral macro domain (Semliki Forest virus, HEV and 
SARS virus) along with a yeast macro domain were compared with the human macro 
domain. The data from this report indicated that viral macro proteins bind poly(ADP-
ribose) and poly(A), but have a low affinity for monomeric ADP-ribose. This implies that 
viral macro domains are functionally different from homologues in the human, and the 
viral macro domain may participate in cellular pathways involving in RNA rather than 
ADP-ribose derivatives (268). Furthermore, other cell-based studies have indicated the 
expression of the macro domain in liver cells, leading to the inhibition of apoptosis since 
the macro domain is functionally related to poly(ADP-ribose) polymerase-1 (PARP-1) 
(12, 43), suggesting that the viral macro domain might regulate apoptosis during viral 
infection as well. Recently, a highly conserved “glycine-triad” (G815-G816-G817) was 
identified downstream of the macro domain of HEV, which is homologous to the rubella 
virus protease-substrate (G1299-G1300-G1301) (282). Mutagenesis assays indicated that 
G816V and G817V mutations in the macro domain are lethal for Sar55 replication in 





heterogeneity in the macro domain may facilitate HEV persistence in HEV infected solid-
organ transplant patients (198). 
Helicase domain 
The next domain downstream of the X domain is the RNA helicase domain, 
which is encoded by many positive-stranded RNA viruses and is essential for their 
replication (146). Helicases are motor proteins which are able to unwind nucleic acid 
strands by using energy derived from ATP hydrolysis , and helicases play an 
indispensable role in many positive stranded RNA viruses (146). Generally, helicases can 
be divided into six superfamilies (SF1-6) (371). RNA virus coded RNA helicases are 
mainly classified into SF1 and SF2. Helicases SF1 and SF2 contain seven signature 
motifs (I, Ia, II, III, IV, V and VI) that form the core of the enzyme (146). The helicase 
domain of HEV belongs to helicase superfamily SF1 and is proposed to possess both 
NTPase activity and an RNA unwinding domain (146, 179). In vitro experiments have 
demonstrated that the purified HEV helicase domain from E. coli has both NTPase and 
RNA unwinding activities. It drives the hydrolysis of rNTPs but also dNTPs with a lower 
efficiency, as well as unwinds RNA duplexes with 5’ overhangs (159). RNA 5’-
triphosphatase activity has also been observed in the HEV helicase domain, which is 
proposed to function along with methyltransferase for catalyzing RNA capping (160). 
Recently, in an in vitro mutagenesis study on HEV helicase demonstrated that motifs  I, 
IV and VI are dispensable, while motifs Ia and III are crucial and unique for HEV 






The last domain of HEV ORF1 polyprotein is the RNA dependent RNA 
polymerase domain (RdRp). All positive-stranded RNA viruses code an RdRp, which is 
necessary for viral replication (270). The RdRp from all positive-stranded RNA viruses 
can be divided into three large supergroups. All RdRp domains contain approximately 
300 amino acid residues, with the central and C-terminal parts showing high similarity 
between each other (177). RdRp from HEV belongs to supergroup III and has the highest 
similarity to the domains in rubella virus and beet necrotic yellow vein virus (BNYVV) 
(179). All eight conserved motifs can be found in HEV RdRp, including an Mg2+ binding 
sequence (GDD), which is essential for RdRp activity. The purified RdRp protein of 
HEV is able to bind the 3’ end of HEV RNA, and two stem-loop structures at the 3’ end 
of the poly(A) stretch are necessary for this binding (5). Expression of the RdRp domain 
in mammalian cells as a GFP fusion protein indicate that it localizes in endoplasmic 
reticulum (ER), which could be a potential replication site for HEV (315). 
The capsid protein encoded by ORF2 
HEV ORF2 encodes the capsid protein, which is the major component of the 
HEV virion. It begins from 37 nt downstream of ORF1, is 1980 nt in length and 
terminates 65 nt upstream of the polyadenylation tail (319). The full-length ORF2 
product is predicted to have 660 aa residues with a molecular mass of 72 kDa (325). 
Recombinant ORF2 protein can bind to the 5′ region of HEV genome (382). The first 
study performed in mammalian cells showed that the ORF2 product exists as an 88 kDa 
protein which carries N-terminal linked glycans and a potential endoplasmic reticulum 





processed and has the potential to form non-covalent homodimers (140). A further study 
from the same group demonstrated Asn-310 in ORF2 to be the major site for 
glycosylation (445). A mutagenesis assay indicated that the N-terminal signal peptide is 
required for its cell surface expression via ER transition, but glycosylation of the capsid 
protein is not required (445).  
Since glycosylation of the capsid protein in non-enveloped viruses is not common, 
it is not clear whether these modifications have biological significance for HEV infection. 
Lately, in a more detailed study, all three putative glycosylation sites (aa137, aa310, 
aa562) were mutated in an infections clone to verify their function. It was found that that 
any mutation in the glycosylation site prevented the formation of viral particles but 
without an effect on virus replication in cells; the first two glycosylation sites prevented 
virion assembly, while the third site was related to virion particle formation and RNA 
encapsulation (100). 
 On the other hand, data acquired in insect cells provided a different conclusion 
regarding ORF2 expression and processing. When expressed in insect cells by the 
baculovirus expression system, ORF2 can be expressed as an insoluble full length protein 
of about 72 kDa, as well as a soluble form of 56.5 kDa which is a processed product of 
the intact p72 kDa form (237). Another group showed that when expressed in SF9 cells, a 
62 kDa product was generated from p72 kDa, which lacks the first 111 aa residues of the 
putative ORF2 product (454). Further study performed in two different insect cell lines 
(SF9 and Tn5) for ORF2 expression showed a soluble form of pORF2 with a molecular 
mass of 50 kDa which lacks the first 111 aa of the N-terminal and the last 52 aa of the C-





assembly is thought to involve dimer formation, and the C-terminus of the recombinant 
ORF2 protein is believed to be responsible for homo-oligomerization (200, 405, 432). A 
3.5-Å resolution crystal structure obtained from HEV VLP indicated that the truncated 
HEV capsid protein has three definite domains designated as S (shell, aa 129-319), M 
(middle, aa 320-455) and P (protruding,  aa 456-606) (437). This VLP particle is 
composed of 60 subunits of the truncated capsid protein, forming icosahedral 2-, 3-, and 
5-fold axes (437). Mutational analyses indicated that the protruding domain is involved in 
binding to the susceptible cells and contains neutralization epitopes (437). Moreover, in a 
more detailed study focusing on the spatial configuration of VLP, ORF2 could be 




The ORF2 product expressed in insect cells is reactive with anti-HEV antibodies 
(402). Another study indicated that anti-HEV serum collected from humans is reactive 
with a synthesized peptide (aa 414-433)  from ORF2 (58). Genetic analysis of ORF2 
showed over 85% homology among the four major HEV genotypes in mammalian hosts 
(257). Amino acid alignment indicates that divergences are mainly in the first 111 aa of 
Fig. 1.3 Schematic illustration of ORF2 product. 
AA: amino acid; S domain: Shell domain; M domain: Middle domain;  






the N terminus, which is not a component of the virion (257). A study manipulating a 
phage display system for overlapping peptides and truncated ORF2 proteins mapped the 
major neutralizing domain to residues 458 to 607, which matches the location of the P 
domain (244, 354, 459). These data provide valuable information for vaccine 
development. The ORF2 truncated protein generated by baculovirus or bacterial systems 
was tested in clinical trials (367, 460). However, a recent study that evaluated cross-
protection against heterologous HEV indicated that pigs vaccinated with truncated capsid 
proteins derived from swine, rat and chicken HEV only generated partial protection 
against a genotype III mammalian HEV (341). 
Additionally, as a structural protein, the HEV capsid protein was found to interact 
with many cellular proteins and play a role in cell signaling. In one study, HEV ORF2 
was found to activate the pro-apoptotic gene CHOP (143). The same study also 
demonstrated that ORF2 increases the expression of Hsp72, Hsp70B and Hsp40, and 
interacts with Hsp72, which may inhibit apoptosis. Moreover, it was demonstrated that 
ORF2 interacts with β-TRCP, a component of the ubiquitination complex that inhibits 
IκBα ubiquitination-mediated NF-κB activation (383). However, these data are all based 
on the overexpression of ORF2 in mammalian cells, which needs to be further verified in 
whole virus infection.  
ORF3-encoded protein  
The ORF3 is the smallest among the three ORFs of HEV and overlaps with ORF2 
by approximately 300 nt in a different reading frame. However, it does not overlap with 
ORF1 (99). The overlapping region (nt 5147 to 5477) had been found to be the most 





proposed that ORF3 codes for a protein with 123 aa and comes from a different 
subgenomic RNA other than that encoding ORF2 (393). However, a later study based on 
an HEV replicon suggested that ORF3 is translated from a bicistronic subgenomic RNA 
at the third AUG at nt5131 for Sar55 and expressed as a protein with 114 aa and 
molecular size of 13 kDa (hereinafter called vp13), which is 9 aa shorter than the 
predicted version (99). This observation has been confirmed by another study (134).  
Sequence analysis has indicated that vp13 is unique and has no homology with 
any other proteins. It contains two hydrophobic domains in its N-terminal half and two 
proline-rich domains in its C-terminal half (121, 154). A phosphorylation site (Ser71) has 
been identified in the first proline-rich domain and can be phosphorylated by MAP kinase 
(446). Furthermore, two PSAP motifs have been identified in vp13, with the first PSAP 
motif located at aa 86-89 and the second located at aa 95-98 (262).  
Although the full functions of HEV vp13 have not been defined yet, some studies 
have suggested that vp13 plays multiple roles during HEV infection. Earlier studies 
focusing on vp13 antigenicity and epitope mapping demonstrated that the last 32 aa of 
vp13 contain an immunodominant region, and a synthesized peptide from that region is 
reactive with anti-HEV serum from a recovered patient (58, 359). However, another 
study which tried to map the T cell epitopes for ORF2 and ORF3 indicated that no T cell 
proliferation was observed when cells were stimulated with peptides from vp13 (4). In 
mutagenesis studies, although vp13 is dispensable for viral replication in cell culture (72), 
it is indispensable for HEV infectivity in vivo, implying an important role for vp13 (134). 
A yeast two-hybrid system was employed to screen for the interaction partners for 





kinase (MAPK) phosphatase and lead to activation of the MAPK (156), suggesting that 
vp13 can modulate host gene expression since MAPK is related to cell signaling and gene 
expression. Chandra et al. found that vp13 inhibits the nuclear translocation of STAT3 
and down-regulates STAT3-mediated gene expression, such as acute-phase response 
proteins (41). The vp13 could also increase the expression of glycolytic pathway 
enzymes by increasing the phosphorylation and transactivation activity of p300/CBP by 
stabilizing HIF-1 transcription factor (253). Furthermore, microarray analysis for Huh7 
cells with vp13 expression suggested that liver-specific genes can be modulated, as vp13 
is able to modulate the phosphorylation of hepatocyte nuclear factor 4 (39).  
The vp13 can also up-regulate mitochondrial voltage-dependent anion channel 
genes, which can protect cells from mitochondrial depolarization and death (254). This 
result implies that vp13 is able to inhibit the mitochondrial apoptosis pathway. The pro-
survival role of vp13 was also demonstrated in another study showing vp13 delays the 
trafficking and degradation of the activated hepatocyte growth factor receptor to prolong 
endomembrane growth factor signaling (40). Additional interacting molecules have been 
identified for vp13 by yeast two-hybrid screens, including α-1-microglobulin, bikunin, 
and bikunin precursor protein (AMBP), fibrinogen β chain and hemopexin (312, 313, 408, 
409).  
Besides yeast two-hybrid screens, overexpression of the vp13-coding plasmid in 
mammalian cells was also employed to elucidate the function of vp13. Studies have 
indicated that vp13 can associate with the cytoskeleton fraction when expressed in cells, 
and deletion of the N-terminal hydrophobic domain of vp13 abolishes this association 





microtubules to form a filamentous pattern in cells; this pattern could be altered by a 
microtubule-destabilizing drug (154). Furthermore, the expression of vp13 leads to an 
elevation in acetylated α-tubulin, indicating increased microtubule stability (154). 
Truncation analysis indicated that both the hydrophobic domains in the N-terminus of 
vp13 are required for its association with the microtubules. Moreover, salt extraction 
studies have suggested that the vp13-microtubule interaction is electrostatic and dynein is 
needed for the interaction. An earlier study showed that vp13 cannot be co-precipitated 
with tubulin by anti-tubulin antibody (446). These results suggest that vp13 may 
associate with microtubules through interactions with other proteins. This microtubule-
like distribution of vp13 suggests that it may play a role in promoting virus egress, as the 
pUL37 protein of herpes virus can interact with dystonin, an important cytoskeleton 
cross-linker involved in microtubule-based transport, in order to promote capsid transport 
on microtubules during egress (283).  
More interestingly, another study using a monoclonal antibody against vp13 to 
capture HEV particles showed that vp13 can associate with virions and support virus 
release (387). This was later confirmed by a cell culture-adapted genotype III HEV strain 
with vp13 deletion, indicating vp13 is required for virion release (435). Studies in Caco2 
and Huh7 cells for the prototype Sar55, genotype I HEV, showed that the intact PSAP 
motif in vp13 is required for virion release (73, 262). For avian HEV, the PSAP motif in 
vp13 has also been found to play a role in virus release (170). It has been revealed that 
the PSAP motif in vp13 is required for the formation of membrane-associated HEV 
particles with the vp13 protein itself associated with lipids. This process is mediated by 





associated with virion during egress, anti-vp13 antibodies are only able to capture HEV 
from the serum, not fecal samples from patients (387). A possible explanation for this is 
that viral particles could lose lipid-associated vp13 after passing through the gut (387). 
The role of vp13 in virus release may be one of its functions during HEV replication, and 
it may explain why vp13 is indispensable during in vivo infection. 
On the other hand, as a small phosphorylated protein, vp13 can be phosphorylated 
at Ser71 by MAPK when expressed in COS1 and Huh7 cells (446). A later study 
indicated that the Ser71 phosphorylation site is required for the ORF2/ORF3 interaction 
as ORF3 can interact with ORF2 in a yeast two-hybrid screen, especially for non-
glycosylated ORF2 (407). This finding also supports a role for vp13 in HEV structural 
assembly. However, a mutagenesis study indicated that HEV lacking the phosphorylation 
site in vp13 was able to replicate its genome in cultured cells, and infection of rhesus 
monkeys with wild type HEV and the phosphorylation site mutant virus induced the same 
viremia and seroconversion (98). These data suggest that phosphorylation of vp13 is not 
necessary for genome replication or for the production of infectious virions. Moreover, in 
addition to phosphorylation and interaction with ORF2, vp13 could form a homodimer 
and the 43 aa domain located in the vp13 C-terminal is responsible for its self-association 
(406).  
Recently, our study indicated that vp13 is able to enhance host interferon 
induction via increasing RIG-I expression and activation  (264). We found that vp13 
extends RIG-I half-life and interacts with N-terminal portion of RIG-I to enhance its 





enhancement of RIG-I mediated IFN induction by vp13, implicating that vp13 may 
contribute to HEV virulence and pathogenesis. 
In summary, as the smallest among the three ORFs of HEV, ORF3 encodes vp13 
that plays an indispensable role in infectivity in experimentally infected animal models. 
However, it appears not required for HEV replication in culture cells. Our current 
knowledge indicates that vp13 is a multifunctional protein. It interacts with many cellular 
proteins, modulates host gene expression and is required for virion release.   
Replication cycle of Hepatitis E Virus  
Due to the lack of an effective in vitro cell culture system for HEV, the replication 
cycle of HEV is largely unknown. The capsid protein is believed to bind to a cellular 
receptor to initiate viral entry, and there is evidence for the binding of recombinant capsid 
protein to the cell surface during HEV entry (110). It is also believed that HEV enters 
liver cells through clathrin-mediated endocytosis (155). However, the exact cellular 
receptor for HEV is still unidentified. One study based on a viral overlay protein binding 
assay (VOPBA) suggested that a protein with molecular weight about 55 kDa could be 
the candidate for HEV entry, but mass spectrometry revealed that this virus binding band 
contained 31 different proteins (452). Another study suggested that aa 458-607 located in 
the C-terminal region of the HEV capsid protein may be the putative receptor binding site 
of HEV virions (110). 
After virus entry into permissive cells, HEV genomic RNA is uncoated by 
unknown mechanisms. In one study utilizing truncated capsid protein HEV239, an 
HSP90-specific inhibitor (geldanamycin) blocked the intracellular transport of the 





may play a role in the intracellular transport of HEV particles. After that, the HEV 
genome will start ORF1 translation, and its genome replication is believed to rely on the 
necessary enzymes encoded by ORF1. Then, with the generation of sub-genomic RNA 
for ORF2 and ORF3 translation, there will be virion packing and egress based on our 
current understanding of the functions of the ORF2 and ORF3 products.  
Cell culture and propagation of Hepatitis E virus  
Since the discovery of HEV, many efforts had been made to develop an in vitro 
cell culture system for it. However, as of now, the cell culture system HEV is limited and 
ineffective. An early study tried to use primary hepatocytes from macaques supplied with 
serum-free medium for HEV propagation; however, virus replication was limited and the 
detection of virions in the medium relied on PCR (394). Almost at the same time, a group 
from Japan reported that HEV isolate 87A was able to replicate in A549 cells with 
cytopathic effect (CPE); however, PCR was used to detect viral RNA in the cell culture 
medium (133). Lately, a group from China also claimed that the A549 cell line could be 
used effectively for passaging two Chinese HEV isolates, but these findings were not 
confirmed for other HEV strains or in other labs (427).  
On the other hand, as the commonly employed method for single-stranded, 
positive-sense RNA virus, transfection of capped RNA from an HEV cDNA infectious 
clone via in vitro transcription to PLC/PRF/5 and Huh7 cells demonstrates limited 
replication of HEV (71). Although cell lysates from RNA transfected cells is infectious in 
rhesus monkeys, cell to cell spread of the virus is not observed (71). S10-3 cells, a 





for the genotype I HEV Sar55 strain but this assay still relies on the transfection of HEV 
RNA (99, 369).  
A Japanese group reported that a genotype III isolate from acute hepatitis patient 
could propagate in PLC/PRF/5 (hepatocellular carcinoma) and A549 (lung cancer) cells 
(272). After A549 cells were seeded in a six-well plate, they were inoculated with HEV 
at 1.0 × 104 and 1.0 × 105 RNA copies per well, and HEV RNA reached the highest titer 
of 107 copies/ml 50 days post inoculation. However, PLC/PRF/5 cells could only support 
as efficient growth as A549 with a higher MOI (with 1.0 × 105 viral RNA copies per 
well). Moreover, in this HEV cell culture system, HEV infected cells need to be 
maintained at 35.5°C and cultured with a mixed cell culture medium (50% Dulbecco's 
Modified Eagle Medium and 50% Medium 199) supplemented with 2% (v/v) fetal bovine 
serum and 30 mM MgCl2. 
Recently, a genotype III HEV strain, Kernow, with an insertion of the human S17 
gene was adapted for cell culture in HepG2/C3A cells (369). The authors speculated that 
this S17 insertion might occur in the HEV patient. The recombinant virus was a minor 
species in the host but selectively adapted to cells after six passages. In a seven-day 
incubation period, the replication of this HEV isolate was 7.5-fold higher in HepG2/C3A 
human hepatoma cells than in Huh7.5, PLC/PRF/5, A549, Caco-2 intestinal cells or 
rhesus kidney cells, suggesting that HepG2/C3A cells were the most permissive. 
Moreover, this HEV isolate was also able to infect a variety of non-primate cells, 
including cow, mouse, chicken, cat, dog and rabbit cells, but with less efficiency. 
In summary, the current cell culture system for HEV has limitations. Until now, 





transfection-based system. On the other hand, although several groups have demonstrated 
that genotype III or IV HEV strains can be adapted to cell culture and is able to re-infect 
new cells, it needs a long incubation time compared to other RNA viruses. Moreover, the 
cell culture adapted Kernow virus may have a different phenotype compared with the 
wild type virus as virus-host recombination occurred in this cell culture adapted virus. 
Transmission and epidemiology of HEV 
The hepatitis E virus is a fecal-oral transmitted viral pathogen. The most common 
source of infection is contaminated drinking water in developing countries. It has been 
estimated that one third of the world total population have been infected by HEV on the 
basis of seroprevalence. However, for a long time, hepatitis E was thought to be a public 
health problem only for developing countries. Hepatitis E is now recognized frequently in 
industrialized countries where it was not thought to be endemic before (76, 145, 185, 252, 
337, 348, 430).  
World Health Organization (WHO) estimated that there are 14 million 
symptomatic cases of HEV infection with 300,000 deaths and 5200 stillborns annually in 
the world (429). According to WHO, hepatitis E is highly endemic in East and South 
Asia, where annual hepatitis E symptomatic cases are estimated at 6.5 million, with 
160,000 deaths and 2,700 stillborn babies. The number of deaths indicates the more than 
50% of global hepatitis E deaths occur in this region. In East Asia, large outbreaks of 
hepatitis E have only been described in China. Hepatitis E accounts for 20%-50% of 
acute hepatitis cases in this region. The seroprevalence of anti-HEV antibodies in the 
region varies from 10% to 50%, indicating that hepatitis E is hyperendemic in this region. 





but variable in size. Hepatitis E virus accounts for 20-60% of sporadic acute hepatitis and 
fulminant liver failure in this region. Specifically, the rates of fulminant liver failure are 
usually higher in pregnant patients. A recent paper reported that HEV infection causes 
49% acute viral hepatitis and 75% fulminant hepatic failure in pregnant women (183). 
However, the seroprevalence rates of prior exposure to HEV are relatively low, being 
10%-40% in most studies.  
In developed countries, such as North America, Western Europe and Japan, no 
outbreaks have been reported. These areas are considered as low or non-endemic for 
HEV. However, there have been sporadic cases of hepatitis E reported. Transmission of 
HEV from animal reservoirs to humans is the major cause of those sporadic cases. A 
series of cases of HEV infection in people who ate undercooked deer meat 6 to 7 weeks 
before the onset of disease have been reported (202, 395, 440). HEV RNA recovered 
from the leftover deer meat was found to be identical in sequence to the HEV RNA 
recovered from the patients (385). Recently, the consumption of shellfish was considered 
a risk factor in a documented case (175). Thus, foodborne infection could occur from the 
consumption of uncooked/undercooked products from infected animals. Moreover, blood 
transfusion-mediated HEV transmission had been also been reported. IgM and IgG 
against HEV have been detected in recipients of blood transfusions (426).  
HEV genotype I is responsible for most endemic and epidemic cases of hepatitis 
E in Asia, and genotype II is prevalent in Central America and Africa (304). There is no 
known animal reservoir for HEV genotypes I and II (426), which may explain why HEV 
infections in developed countries are mainly caused by genotype III and genotype IV, as 





Pathogenesis, clinical signs and diagnosis of HEV  
Hepatitis E virus infection causes acute hepatitis with a mortality rate from 0.5 to 
3% in young adults (139). However, according to WHO, acute hepatitis and fulminant 
liver failure caused by HEV account for 20%-60% of the total cases in South Asia. 
Remarkably, death resulting from HEV-related fulminant liver failure has drastically 
increased to 30% in pregnant women in their third trimester of gestation (139). Generally, 
HEV has an incubation period of 3 to 8 weeks (34). The initial symptoms of acute 
hepatitis E are unspecific and flu-like, such as myalgia, arthralgia and weakness. After 
this short prodromal phase, a period of symptoms such as vomiting, jaundice, itching, 
uncolored stools, darkened urine and jaundice could last for days to several weeks 
accompanied by increased levels of liver transaminases, bilirubin, alkaline phosphatase 
and γ-glutamyltransferase (123, 426). Current case reports indicate that most cases are 
self-limited and do not result in chronic hepatitis (123). Recently, an investigation was 
conducted by Kumar et al. on pregnancy outcomes in hepatitis E (183). In their report, 
higher HEV viral loads were observed in pregnant women with acute viral hepatitis and 
fulminant hepatic failure, as well as higher levels of TNF-α, IL-6, IFN-γ and TGF-β1, 
which suggests that high cytokine levels are responsible for severe liver injury in HEV 
infection (183). 
Chronic infection of HEV has been identified almost exclusively among 
immunocompromised persons, including organ transplant recipients, patients receiving 
cancer chemotherapy and human immunodeficiency virus (HIV)-infected persons (123). 
However, although such cases are rare, chronic HEV infection may occur in adults 





organ transplant recipients, the chronic course leads to persistent increases in levels of 
alanine aminotransferase, significant histological activity and fibrosis in some cases (426). 
On the other hand, although there have been reports showing that HIV infected 
individuals have higher positive results in anti-HEV antibody tests than individuals 
without HIV infection, but chronic hepatitis E was not described in HIV-infected patients 
before 2009 (426).  
Besides hepatitis, extrahepatic manifestations have been documented as well. 
Neurological disorders, such as polyradiculopathy, Guillain–Barré syndrome, bilateral 
brachial neuritis, encephalitis and proximal myopathy have been reported in patients with 
acute and chronic HEV infections (150). Furthermore, a recent report provided evidence 
that extrahepatic replication of hepatitis E virus in the placenta of infected mothers and 
replication of HEV in the placenta may be associated with fetal mortality (35).  
Recently, there was a report focusing on the association between the outcome of 
HEV infection in solid-organ transplant patients and the genetic heterogeneity of HEV 
quasispecies in ORF1. This report demonstrated that both sequence entropy and genetic 
distance during the hepatitis E acute phase were higher in patients whose infection 
became chronic than in those who cleared the virus (198).  
Although diagnostic tests for HEV are commercially available, none of them have 
been formally approved in the United States by the Food and Drug Administration (FDA) 
(123). Current tests mainly target anti-HEV antibodies, including IgG and IgM. However, 
several assays are based on antigens expressed by a single HEV genotype, especially 
genotype III, and might be limited for the detection of all HEV genotypes. Indeed, there 





which may account for the discrepancies among positive rates of anti-HEV antibodies in 
various populations (65, 118, 234). On the other hand, HEV RNA can also be detected in 
blood and stool for several weeks after acute HEV infection. However, current RNA tests 
are still experimental since they have not been standardized yet (426). Furthermore, 
serologic and virological tests are also available for free from the Centers for Disease 
Control and Prevention.  
Treatment and Prevention of HEV  
HEV infection causes a self-limited disease and almost all infected individuals are 
able to clear the HEV infection spontaneously. Although the mortality in young adults is 
0.5%-3%, the deaths caused by fulminant liver failure can increase to 30% in pregnant 
women during their third trimester of gestation in South Asia (139). Therefore, antiviral 
therapy may be needed for some acute cases. Although no specific treatment has been 
approved for HEV, off-label application of ribavirin for HEV has demonstrated 
promising results in both acute and chronic hepatitis E patients (91, 152, 230). For 
immunosuppressed patients, a reduction of immunosuppression has shown efficacy in the 
treatment of chronic HEV infection (426). Moreover, application of pegylated interferon 
in combination with ribavirin has been reported as well as a treatment for chronic HEV 
infection (426). 
Current prevention for HEV in developing countries relies on sanitary measures, 
such as providing clean water. In developed countries, prevention is more complicated 






Since in vitro culturing of HEV is limited and ineffective, HEV vaccine 
development mainly focuses on the expression of the capsid protein as a subunit vaccine. 
The capsid protein shares over 85% homology among the four major HEV genotypes in 
mammalian hosts (257). Currently, the capsid protein expressed by insect cells via 
baculovirus or bacterial vectors has been tested in clinical trials. The first candidate was a 
56 kDa protein encoded by ORF2 and expressed in insect cells. In a phase 2 trial in Nepal, 
the vaccine was well-tolerated and highly immunogenic, with 95% efficacy for protection 
against hepatitis E (367). The second vaccine, HEV 239, was a 26 kDa truncated protein 
(aa 358-606) of ORF2 product expressed in E. coli (201). This vaccine was well tolerated 
with an efficacy of 100% protection after three doses in a tested population of China, 
which included both men and women aged 16–65 years (460). The HEV 239 vaccine was 
approved in China in 2012. Whether it will be endorsed in other countries or how 
effective it is against all genotypes of HEV remains unknown.  
Summary 
More than 20 years have passed since the discovery and complete genome 
sequencing of the hepatitis E virus. Our understanding of HEV is still limited, though 
ongoing research continues to reveal more and more information about this virus. 
Currently, we know that HEV is not only a public health concern in developing countries 
as previously thought, but also a health concern with a more complicated background in 
developed countries. More and more animal reservoirs have been revealed and we now 
understand that HEV is a zoonotic and foodborne disease. On the one hand, although 
approved in China, the vaccine is still unavailable to most of the world despite the fact 





world. On the other hand, virus specific treatment for HEV is not available yet. Although 
the off-label using of pegylated IFNs and anti-viral drugs for general purposes have 
demonstrated efficacy against HEV, safety is still a concern as no validation has yet been 
conducted for these treatments. Furthermore, due to the absence of a suitable animal 
model and an effective cell culture system, many details about this virus, such as its 
pathogenesis, strain differences, genotype differences, molecular mechanisms and 
vaccine efficiency for cross protection are still missing.  
In this study, we attempted to determine the mechanism that HEV interferes with 
host interferon induction and signaling, and to identify the viral proteins responsible for 
this interference. As interferons play key roles in host innate immunity against viral 
infection and in the development of adaptive immunity, understanding the mechanism of 
how HEV evades host innate immunity will provide valuable information for studies on 










Chapter 2: Interferons and Induction 
Introduction 
Host immunity can be divided to two broad categories: innate and adaptive. 
Vertebrates have developed strong innate immunity against viruses, and the key player in 
this system is interferons. Since the discovery of interferon in the 1950s, numerous 
studies have been conducted on this protein family. By the technology of molecular 
biology, many genes coding for the interferons have been cloned and sequenced, as well 
as expressed in E. coli. With the advantage of purified interferons, interferon-based 
therapy had been developed and applied to treat cancer and viral infection. In this chapter, 
interferons, their classification, function and induction are reviewed in detail.  
Interferons and Their Classification  
Interferons are a large family of proteins which are genetically and functionally 
related (193). The discovery of these mediators occurred in the 1950s, when researchers 
observed that virus-infected cells could be made resistant to secondary viral infection 
under certain circumstances. Similarly, it was also observed that treatment of cells with 
inactivated virus made cells resistant to infection by the same but live virus. Later, the 
term “interferon (IFN)” was created to describe a special substance, possibly produced by 
cells, which could interfere with virus replication. However, due to technical limitations, 
it took more than two decades until interferons could be purified for further analysis (290, 
334). The antigenic differences between IFNs generated by human fibroblasts and 
leukocytes led to the idea that IFNs constitute a protein family (108). Currently, the 





activity, stimulation of T cell cytotoxic activity and modulation of the immune response 
(290). Since their approval, purified interferons have also been used for the treatment of a 
variety of cancers and viral diseases (290). 
Interferons are divided into three different types: type I, type II and type III. In 
humans, type I interferons, generally called IFNs, are the largest IFN family, which 
includes IFN-α, IFN-β, IFN-ε, IFN-κ and IFN-ω (292, 412). They belong to the class II 
family of α-helical cytokines, which includes type II IFN-γ, the newly identified type III 
IFNs, IL-10 and several IL-10 homologs (62, 181, 291). Type I IFNs are encoded by 
individual genes except IFN-α, which has 13 subtypes (79). IFN-δ, IFN-τ and IFN-ζ (or 
limitin) have also been identified as type I IFNs in swine, ruminants and mice, 
respectively (79). Almost all cell types are capable of producing IFN-α/β; however, 
plasmacytoid dendritic cells (pDC) are considered as the major source for IFN-α 
production during the course of an infection (217, 370). All type I IFNs binds a 
ubiquitously expressed heterodimeric receptor complex, which includes the IFN-α 
receptor 1 (IFNAR1) and IFN-α receptor2 (IFNAR2) as subunits. Data suggest that 
IFNAR2 serves for ligand binding, but both subunits are required to activate downstream 
signaling (397). However, the various subtypes of type I IFNs display different binding 
affinities for the receptor complex and thus lead to various outcomes with respect to their 
antiviral, antiproliferative and immunomodulatory activity (138, 148, 256). 
The type II interferons include only IFN-γ, which functions as a homodimer (79). 
unlike type I IFNs, IFN-γ production is restricted to activated T cells, natural killer cells 
and macrophages (413). Signaling for IFN-γ is transduced via the IFN-γ receptor 





with further binding of two IFNGR2 subunits, which results in receptor activation (420). 
IFNGR is ubiquitously expressed, which means nearly all cell types are capable of 
responding to IFN-γ (413). IFN-γ plays a major role in establishing cellular immunity; 
however, it is also able to induces expression of a group of genes that respond to type I 
IFN treatment (56, 197). 
The type III interferons are a newly discovered family of interferons which 
comprise IFN-λ1, IFN-λ2, IFN-λ3 (also known as interleukin (IL)-29, IL-28A, and IL-
28B, respectively) (79). They were initially named “interferon-like cytokines” because 
IFN-λ is functionally similar to type I IFNs but has a distinct gene sequence and 
chromosomal location (397). Besides, IFN-λ signals through a heterodimeric receptor 
composed of IFRL1 (or IL-28R) and IL-10R2, which are different from type I IFN 
receptors (79, 291, 292). However, IFN-λ activates the same pathway and similar gene 
expression as type I IFNs. Recently, IFN-λ4 was described as the fourth member of the 
type III IFNs (301). 
After the discovery of IFNs and their antiviral activity, viral RNA was proposed 
to be the potential inducer. Many early studies focused on the identification of possible 
nucleic acid inducers and numerous synthetic and biological RNAs were tested for this 
purpose. Unlike ssRNA, DNA or RNA:DNA hybrids, the dsRNA was found to be a 
potent trigger of the interferon response (28). Specifically, dsRNA from bacteria, reovirus, 
vaccinia virus and synthetic polyinosinic:polycytidylic acid (polyIC) were shown to be 
potent activators of IFN production (28). However, only recently have we begun to 





The discovery of Toll and the Toll-dorsal pathway in Drosophila led us to 
understand that there are conserved signaling pathways across the plants and animals as a 
common defense against pathogens (29). Identification of the first Toll homologue in 
humans finally led us to gain the concept of Toll-like receptors (TLRs) (241). The TLRs 
were subsequently shown to distinguish unique molecules present in a variety of 
pathogens from bacteria, fungi to viruses (239). Now, we understand that pathogens are 
recognized by a group of pattern-recognition receptors (PRRs). Besides membrane-
associated TLRs, there are another group of PRRs called RIG-I-like receptors (RLR), 
which comprise the cytoplasmic sensors of viral nucleic acids (25). Taken together, while 
the host IFN response plays a key role during the early stage of viral infection, host PRRs 
for RNA viruses include the RLR and TLR pathways. Both RLR and TLR3 can 
recognize double-stranded RNA (dsRNA) of the viral genome or replication intermediate 
of RNA viruses. Activation of RLR and TLR3 signaling leads to the activation of 
interferon regulated factor-3 (IRF3), IRF7 and NF-κB. Those transcription factors 
translocate to the nucleus and result in the induction of type I IFNs and expression of 
inflammatory cytokines. In the following section, Toll-like receptors, RIG-I-like 
receptors and their corresponding signaling pathways are discussed further. 
Toll-like Receptor Pathway 
Discovery of Toll in Drosophila  
Toll is a gene from Drosophila and was identified during a study for genes 
essential for the establishment of the dorsal-ventral axis in Drosophila during embryo 
development (269). Toll contains an extracellular domain which consists of leucine-rich 





of proteins involved in some form of protein-protein interaction, such as receptors and 
adhesion molecules (388). The cytoplasmic domain of Toll shows high similarity to the 
cytoplasmic domain of the mammalian interleukin 1 type I receptor (IL-1RI) (89, 353). In 
1994, the ligand of Toll in Drosophila, a novel secreted protein encoded by 
the spätzle gene, was identified and confirmed to be necessary to establish the dorsal-
ventral pattern of the Drosophila embryo (258). However, a later study demonstrated an 
additional, non-developmental role played by Toll that the activation of Toll could result 
in an immune response in Drosophila cell lines. This kind of immune response is 
mediated by transcript factors from the Rel family, i.e. Dorsal-related immunity factor 
(Dif) and Dorsal, both of which are NF-κB like transcript factors in Drosophila (331). 
Conclusive evidence from in vivo experiments demonstrated that Toll mediates signaling 
pathways and the extracellular Toll ligand, spätzle, controls the expression of the 
antifungal peptide gene drosomycin in Drosophila adults (192). Mutations in the Toll 
signaling pathway dramatically reduce the survival of Drosophila after fungal infection 
(192). These discoveries led to the formation of a conserved signaling pathway of the 
immune response: the Drosophila Toll-Dorsal pathway, which is considered the 
homologue of the interleukin-1 receptor (IL-1R)-NF-κB pathway in mammals (29). 
Discovery of Toll-like receptors in mammalian hosts  
After revealing the role played by Toll in the immunity of Drosophila, researchers 
started to look for the analogous genes in humans that are involved in this evolutionally 
conserved immune signaling pathway. However, the idea for the existence of certain 
cellular receptors which could sense pathogens and deliver signals to cells was generated 





known as Toll-like receptor 4 (TLR4), was cloned and confirmed to induce the activation 
of NF-κB and the expression of NF-κB activated inflammatory cytokines (241). However, 
since little knowledge about the existence of the natural ligand or the human homologue 
of the spätzle gene was available for the first discovered Toll homologue in humans, the 
strategy employed to confirm its function relied on artificial modification of this Toll 
homologues. Based on the previous data for generating the constitutively active mutant of 
Drosophila Toll, researchers generated a similar mutated construct and fused it to a CD4 
ectodomain as a marker for verifying the expression of the hybrid protein. When this 
CD4–Toll fusion protein was overexpressed in a macrophage-derived cell line, it 
constitutively activated NF-κB and resulted in the upregulation of inflammatory 
cytokines as well as costimulatory molecules, as originally predicted (241). Later, a total 
five Toll homologues from human were identified, and designated as TLR1 to 5 (326).  
The term TLR was initially assigned to describe a Toll related gene that 
contributes to hedgehog function in the adult eye of Drosophila in 1994 (44). Using of 
this term occurred earlier than the discovery of Toll as an immune response related 
receptor. However, since the discovery of Toll homologues in mammalian hosts, TLR 
have been assigned to describe a new receptor family more closely related to Drosophila 
Toll homologs rather than to vertebrate IL-1Rs (326). Currently, a total of 13 TLRs have 
been identified in humans and mice (TLR1-13) (33, 48, 49, 187, 391, 449). TLR1 to 
TLR10 are expressed in humans, while TLR11 to TLR13 are found exclusively in the 
mouse. There is indeed a TLR10 homologue identified in the mouse; however, a 
retroviral insertion disrupted the TLR10 gene and rendered it non-functional (107). 





not found in humans. Some TLRs, such as TLR14, TLR5S, TLR20 and TLR21 have 
been identified in Takifugu pufferfish and catfish, and may be found in non-mammalian 
species with unique properties distinct from those in mammals (23, 278, 323). Of the 
human TLRs, TLR3, TLR7, TLR8 and TLR9 are membrane proteins localized in the 
endosome while the remaining TLRs are mainly locate on the cell surface (167).  
TLR ligands  
After the discovery of TLRs in humans, a key question remained unanswered: Do 
human TLRs recognize natural ligands from pathogens or are there human homologues 
of the spätzle gene that serve as  ligands for TLRs (240)? Data from HEK293 cells 
indicated that TLR2 mediates LPS-induced signaling when co-expressed with CD14 
(438). The conclusive answer came unexpectedly from a study in a mutated TLR4 gene 
in the LPS-unresponsive C3H/HeJ mouse strain (297). Before the identification of TLR 
in mammals, researchers were unable to identify the gene responsible for the LPS 
mediated response in different mouse strains with different phonotypes in their response 
to LPS stimulation, and they termed this proposed gene LPS (18, 250, 330, 379). In 1998, 
a mutation in the TIR domain of TLR4 was finally identified that led to defective LPS 
signaling in C3H/HeJ and C57BL/10ScCr mice, which  confirmed that LPS is the ligand 
for TLR4 (297). Later, TLR4 was confirmed to be the product of the proposed LPS gene 
(127). Furthermore, other studies indicated that another molecule, MD-2, which non-
covalently binds to the extracellular domain of TLR4, serves as the real “receptor” for 
LPS, whereas TLR4 serves as the signal-transducing component of the larger “TLR4 





TLR1 in association with TLR2 as a heterodimer recognizes peptidoglycan and 
lipoproteins (77, 142, 356). The dsRNA is recognized by TLR3 (11). Bacterial flagellin is 
recognized by TLR5 (109). TLR6 recognizes lipopeptide cooperatively with TLR2 (77). 
TLR7 mainly recognizes single-stranded RNA, a common feature of most RNA viral 
genomes. Some artificially synthesized compounds, such as imiquimod, can be 
recognized by TLR7 as well (114). TLR7 and TLR8 are functionally related, as TLR8 
recognizes viral RNA and self-RNA within snRNP autoantibody complexes (83). 
Unmethylated CpG DNA derived from bacteria is recognized by TLR9 (115). Currently, 
no specific ligand had been identified for TLR10. It has been shown that TLR10 plays a 
role in mediating bacterial peptidoglycan-induced trophoblast apoptosis, which implies 
that TLR10 may recognize a bacteria-derived component (261).  
In summary, within the TLR family, TLR3, 7, 8, and 9 represent a subfamily that 
is localized in intracellular compartments, such as endosomes and the endoplasmic 
reticulum (ER), where they recognize viral nucleic acid species (167). There is cell-
specific expression of those four TLRs. Innate immune cells express the endosomal TLR 
7, 8 and 9, which sense GU-rich RNA and CpG-containing DNA, while TLR3 is 
expressed in broad cell types, such as endothelial cells, fibroblasts and astrocytes (349). 
On the other hand, the other subfamily includes TLR1, 2, 4, 5, and 6, which are localized 
on the cell surface and mainly recognize bacterial cell wall components (167).  
Recently, the connection between autoimmune disease and TLRs activated by 
endogenous ligands was revealed (116). There is increasing evidence indicating that 
some endogenous ligands can activate TLR7 and TLR8 and result in autoimmune disease 





some autoimmune diseases such as rheumatoid arthritis. Endogenous DNA fragments 
generated during cell death, either apoptosis or necrosis, are believed to serve as the 
endogenous ligand for these TLRs (116, 295). A full list of TLRs ligands is listed in 
Table 2.1 below. 
 
 
         Table 2.1 Toll like receptors and their ligands 
 
 
TLRs Adaptor(s) Ligand 
TLR1 MyD88 Peptidoglycan/ 
lipoproteins 
TLR2 MyD88 Peptidoglycan/ 
lipoproteins 
TLR3 TRIF dsRNA 
TLR4 MyD88/TRIF/TRAM/TICAM LPS 
TLR5 MyD88 Bacterial flagellin 
TLR6 MyD88 lipopeptide 
TLR7 MyD88 ssRNA 
TLR8 MyD88 ssRNA 
TLR9 MyD88 CpG DNA 
TLR10 MyD88 unknown 
TLR11 MyD88 Unknown  
TLR12 MyD88 Unknown 






TLR signaling  
TLRs are believed to function as dimers. Schematic illustration of the TLR 
signaling is shown in Fig 2.1. After recognition of their ligands, TLRs activate the same 
signaling components as those used in IL-1 receptor (IL-1R) signaling due to a conserved 
Toll-IL-1R (TIR) domain in intracellular regions (259). As a result, TLRs recruit a set of 
adaptor proteins with TIR domains by homophilic interaction of their TIR domains. 
Those adaptor molecules include myeloid differentiation primary response gene 88 
(MyD88), TIR-containing adaptor protein/MyD88-adaptor-like (TIRAP/MAL), TIR-
containing adaptor inducing interferon-β/TIR-domain-containing adaptor molecule 1 
(TRIF/TICAM1) and TIR-domain-containing adaptor molecule/TRIF-related adaptor 
molecule 2 (TICAM2/TRAM) (166). Adaptor molecules used by TLRs are varied for 
different TLRs. TLR4 uses all four adaptors while TLR3 uses only TRIF (166).  
The most well-known adaptor molecule for TLRs is MyD88, which is utilized by 
all TLRs except TLR3. MyD88 is composed of a death domain as well as a TIR domain. 
Upon TLR activation, a homophilic interaction occurs between the death domain of 
MyD88 and members of the IRAK (IL-1 receptor-associated kinase) family, including 
IRAK1 and IRAK4 (10, 428). IRAK4 is initially activated, which in turn phosphorylates 
and activates IRAK1. Then, phosphorylated IRAK4 and IRAK1 dissociate from MyD88 
and interact with TRAF6, which is a RING-domain E3 ubiquitin ligase. TRAF6 promotes 
the Lys63-linked polyubiquitination of itself and NEMO (42). Ubiquitinated NEMO and 
TRAF6 subsequently recruit a protein kinase complex involving transforming growth 
factor-β activated kinase1(TAK1) and TAK1 binding proteins (TABs) (3). TAK1 and the 





and MAPK. TAK1 promotes downstream activation of the IκB kinases (IKK) IKKα and 
IKKβ. These IKKs directly phosphorylate the inhibitory IκB family, which normally 
sequester NF-κB in its inactive form in the cytosol. However, phosphorylation of IκB 
leads to its polyubiquitination and degradation, which enables the activation and nuclear 
translocation of NF-κB. The activation of the canonical NF-κB pathway results in  the 
induction of inflammatory cytokines and co-stimulatory molecules (259). 
A notable function of MyD88 is that signaling transduced via MyD88 due to 
activation of TLR7 and TLR8 in plasmacytoid dendritic cells (pDCs) results in induction 
of IFNs (165). TLR7 and TLR9, are selectively expressed by pDCs (also known as 
professional IFN-producing cells), which are a subset of DCs with a plasmacytoid 
morphology and unique in their capacity to rapidly secrete type I IFNs in response to 
viral infection (50, 217). In pDC, IRF7 is constitutively expressed and binds MyD88 to 
forms a signaling complex with IRAK4, TRAF6, TRAF3, IRAK1 and IKKα (122, 168). 
Within this complex, IRF7 becomes phosphorylated, dissociates from the complex, and 
translocates into the nucleus to activate IFN induction upon activation of TLR7 and 
TLR8. 
Besides MyD88, TRIF is another adaptor molecule that is specially utilized by 
TLR3 and represents another important pathway for TLR signaling (166). Upon 
activation of TLR3 by dsRNA, TRIF interacts directly with the TIR domain of TLR3 
(273). TRIF also directly binds TRAF6 via its TRAF6-binding motifs in the N-terminal 
region (343). TRAF6 then activates TAK1 in a manner similar to that of the MyD88-
dependent pathway for NF-κB activation. On the other hand, TRIF has been confirmed to 





TRAF6; the TANK family protein NAK-associated protein 1 (NAP1) might facilitate the 
interaction of both kinases with TRIF (342, 343). TBK1 and IKKε possess essential roles 
in the induction of type I IFNs through phosphorylation and activation IRF3 and IRF7 
(365). Upon activation, IRF3 forms a homodimer, which translocates to the nucleus and 
binds to its target sequences, such as the promoter region of the IFN-β gene. Thus, there 






























TIRAP and TRAM are another two adaptors that are less investigated, but still 
play important roles in TLR signaling. Their functions are related to TLR4-mediated 
signaling. TLR4 is the only TLR that uses all four adaptors. With assistance from TRAM, 
TLR4 can function via TRIF as well to activate TLR3-TRIF-IKKε (TBK1)-IRF3 
signaling axis. TRAM, also known as TICAM-2, acts as a bridging adaptor between 
TLR4 and TRIF (275). TIRAP has a crucial role in the MyD88-dependent signaling 
pathway shared by TLR2 and TLR4. Just like TRAM, TIRAP serves as a “bridge” for 
MyD88 and receptors and thus activates NF-κB (124, 147). Taken together, as the 
consequence of activation, all TLRs commonly promote chemokine and pro-
inflammatory cytokine expression via NF-κB. However, the hallmark of endosomal 
TLR3, 7, 8 and 9, which sense nucleic acids, is the induction of type-I IFNs (167). A 
schematic illustration of TLR mediated signaling is shown in Fig. 2. 1. 
RIG-I  like Receptor Pathway  
Discovery of the RIG-I like receptor 
 Retinoic acid-inducible gene I, or RIG-I (also known as DDX58), is a member of 
the so-called DExD/H box RNA helicase family. DExD/H box RNA helicase and its 
related DEAD box helicase, named according to one of the conserved protein motifs, 
belong to helicase superfamily 2 (94, 212). This is the largest helicase group and, in fact, 
a subset of it includes proteins from E. coli, eukaryotes, even from DNA and RNA virus 
(94, 212). RIG-I-like receptors (RLRs) currently include three members: RIG-I , 
melanoma differentiation-associated gene 5 (MDA5, also known as Helicard or IFIH1) 
and Laboratory of Genetics and Physiology 2 (LGP2) (236). Unlike membrane-





from viruses, bacteria and fungi, RLRs are cytoplasmic proteins that are specific for 
detecting RNA derived from viruses in the cytosol (349). 
RIG-I was originally identified as a gene induced by retinoic acid during the 
differentiation of an acute promyelocytic leukemia cell line (136, 453). In 1997, a 
Chinese research group from the Shanghai Institute of Hematology, which focused on 
employing all-trans retinoic acid (ATRA) as a treatment for acute promyelocytic 
leukemia, cloned a novel set of ATRA-inducible genes when using retinoic acid to induce 
the differentiation of an acute promyelocytic leukemia cell line. This group named these 
genes “RIG-A, RIG-B, RIG-C,” and so on. They deposited the sequence of the genes into 
GenBank, including the sequence for RIG-I (215, 236). Later, another study identified a 
RIG-I homologue in swine, and named it RNA helicase induced by virus (RHIV-1). This 
gene was upregulated when porcine alveolar macrophages were infected with porcine 
reproductive and respiratory syndrome virus (PRRSV) (453). Another group from Japan 
also reported that stimulation of endothelial cells with lipopolysaccharide (LPS) led to the 
up-regulation of RIG-I (136). Since then, more reports have indicated that RIG-I can be 
up-regulated in cells infected with a virus or cells treated with IFN-γ (52, 255). Taken 
together, the earlier reports connected RIG-I with innate immunity and IFNs.  
The first report to describe the function of RIG-I came from Yoneyama et al., who 
found that the helicase domain of RIG-I is responsible for dsRNA recognition and the 
caspase activation and recruitment domain (CARD) for transmitting the signal 
downstream, leading to the activation of NF-κB and IRF3 and then IFN induction (442). 





databases for RIG-I related genes, leading to the discovery of two other members of the 
RLR family, MDA5 and LGP2 (441).  
MDA5 is another member of the RLR family. Similar to RIG-I, MDA5 was 
identified in a differentiation induction subtraction hybridization (DISH) screen which 
was designed to define genes regulated by the induction of terminal differentiation in 
human HO-1 melanoma cells (130, 131). The genes identified by the DISH screen were 
named melanoma differentiation-associated (MDA) genes. MDA5 was one of these novel 
genes that was induced by IFN-β in human melanoma cells and had melanoma growth-
suppressive properties (153). MDA5 shares 23% and 35% identical aa with RIG-I in the 
CARD and helicase domains, respectively (441).  
LGP2, the latest member of the RLR family discovered, was identified based on a 
set of studies in mammary gland development and remodeling, which are regulated by 
two members of the STAT (signal transducer and activator of transcription) family, 
STAT3 and STAT5. Since Stat3, Stat5a, and Stat5b are closely related in a region of 
mouse chromosome 11, this led the research team to hypothesize that additional genes 
involved in mammary gland development might harbor in this locus (53, 251). Finally, 
two novel genes, Lgp1 and Lgp2, were identified and LGP2 was found as a cytoplasmic 
protein harboring a DExH/D-box helicase domain (53). Unlike RIG-I and MDA5, which 
contain both the CARD and helicase domains, LGP2 contains only the helicase domain 






Ligands of RLRs  
RLRs present in the cytosol of all cell types induce type I IFNs and cytokines 
upon activation (349). As RNA helicases, RLRs mainly recognize RNA molecules 
derived from viruses, and in some cases, RNA from bacteria (349). However, ligand 
preference varies among different RLRs. Specially, even though the details of the RLRs 
ligands have been revealed, there are still many questions remaining. Currently, RIG-I is 
better defined than MDA5 and LGP2, and considerable efforts have been made to 
identify its ligands.  
Initially, polyIC was used as an artificial ligand for RIG-I to activate IFN 
production, consistent with a previous concept of dsRNA as a physiological viral trigger 
for IFN induction due to the simple explanation that RNA viruses are bound to make 
mistakes during replication and are therefore likely to expose at least some dsRNA 
molecules in the cell (28). However, this assumption is questionable. Studies employing 
dsRNA-specific antibodies have shown that positive-stranded RNA and DNA viruses 
make dsRNA during replication; however, negative-strand RNA viruses do not appear to 
produce detectible amounts of dsRNA, such as influenza A virus (425). On the other 
hand, an important addition to this field was the discovery that a 5′ triphosphate (5′ppp) 
group on an RNA molecule serves as a activator of RIG-I in addition to dsRNA (125, 
294). This discovery gives a potential explanation to the earlier observation that 5' 
triphosphate bearing siRNA generated from in vitro transcription is able to induce 
interferon induction, while removing the 5' triphosphate from artificially synthesized 





On the contrary, later studies challenged the earlier observation that the 5' 
triphosphate alone is sufficient for RIG-I activation and indicated the requirement for a 
double-stranded component in addition to the triphosphate (28). Specifically, synthetic 
5′ppp ssRNA was not capable of inducing IFNs when introduced into cells, while the 
same RNA molecule generated by in vitro transcription served as a competent activator 
of the IFN response since the RNA mixture from the T7 transcript contained a significant 
portion of dsRNA molecules (28). Further characterization of RIG-I activation 
requirements showed that dsRNA complementarity of at least 10–18 nt is required at the 
5′ppp containing end in order to induce RIG-I activity. These types of RNA molecules 
can form a panhandle structure,  and is supported by the data that ends of defective 
interfering (DIs) genomes from negative-stranded RNA viruses are very potent IFN 
inducers (378). Thus, for a negative-stranded RNA virus, the complementary 5′ and 3′ 
terminal sequences of its genomes bear the potential to hybridize as 
dsRNA panhandle structures with blunt ends and 5′ppp groups, thereby meeting the 
requirements of a RIG-I ligand (351).  
In addition to 5' triphosphate dsRNA, another study defined the RIG-I ligand as 
blunt-ended dsRNA longer than 23 bp with higher activity when the RNA contains two 
blunt ends (350). Since the dsRNA antibody recognizes dsRNA longer than 40 bp, this 
ligand size requirement gives a potential explanation for why dsRNAs generated by 
negative-stranded RNA virus replication were not detected since they maybe too short for 
the antibody detection (349). Moreover, a recent study indicated that RIG-I is also 





endogenous RNA polymerase III, which generates 5′triphosphorylated AU-polymers in 
the cytosol to stimulate RIG-I (47).  
There has been less attention on the ligand of MDA5. Although polyIC indeed 
binds and stimulates RIG-I, it is worth noting that polyIC fails to induce IFN- when 
injected intravenously into MDA5-deficient mice or transfected in vitro into MDA5-
deficient cells (93, 162). While RIG-I is essential for interferon induction for 
paramyxoviruses, influenza virus and Japanese encephalitis virus, MDA5 is critical for 
picornavirus detection (162). This implies that MDA5 and RIG-I helicases have 
differential roles in the recognition of RNA viruses. Another study demonstrated that 
MDA5 was only stimulated by long polyIC fragments when using polyIC fragments of 
different sizes generated from RNase-III digestion as the activator (161). Briefly, dsRNA 
of 1 kb was entirely dependent on RIG-I for IFN induction, while increasing the length to 
4 kb progressively led to dual MDA5 and RIG-I dependence. MDA5 can recognize 
dsRNA more than 7 kb long. This also shows that viral dsRNAs differentially activate 
RIG-I and MDA5, depending on their length as well. Furthermore, an mRNA fragment 
from the negative-stranded RNA parainfluenza virus 5 activated type-I IFN expression in 
a MDA5-dependent manner (225). Since type I IFN induction by this mRNA fragment 
requires the involvement of RNase L, it implies that RNase L may recognize and process 
viral mRNA into a MDA5-activating structure (225). 
As the third member of the RLRs, LGP2 is not fully understood and the current 
data on its function are controversial. No specific research has been performed on ligand 





domain, suggesting a putative ligand sequestering role (349). Indeed, earlier reports 
suggested an immune suppressive function for LGP2 (176, 332, 339).  Moreover, a 
mutant LGP2 with abolished RNA binding ability was still able to inhibit RIG-I mediate 
signaling (205). However, further studies on LGP2-deficient mice revealed an 
indispensable role of LGP2 for the immune response to viruses that are mainly detected 
by MDA5 (344, 417). In some cases, an impaired RIG-I antiviral response was observed 
as well (344). Another study also demonstrated that LGP2 contributed to sustained RLR 
signaling for IFN-β expression in myeloid cells, and that LGP2 promotes an essential 
pro-survival signal in response to antigen stimulation to induce CD8+ T cell expansion 
and effector functions against divergent RNA viruses (384). Therefore, although no 
finalized conclusion has yet been made, LGP2 appears to have a modulatory role in fine-
tuning the innate immune response to viruses depending on the context of viral infection.   
Collectively, the current data indicate that RIG-I and MDA5 recognize different 
types of viruses with a possible overlapping recognition by both, while LGP2 plays a role 
as a potential regulator. However, both RIG-I and MDA5 require the same adaptor 
molecule, mitochondrial antiviral signaling (MAVS) (also known as virus-induced 
signaling adaptor (VISA), IFN-β promoter stimulator 1 (IPS-1) and the CARD adaptor 
inducing IFN-β (Cardif)) to activate innate immune defense. In the next section, the 
downstream signaling pathway of RLRs will be discussed. 
              Signaling of RLRs 
When RLRs were found to be the intracellular receptor of viral RNAs, it was less 





IRF3, IRF7 and NF-κB, which are required for IFN transcription and utilized by TLRs. 
Soon thereafter, MAVS was identified as the necessary adaptor for RLR signaling from 
different research groups with different names (MAVS, IPS-1, VISA or Cardif. 
hereinafter, MAVS is used) assigned to the same molecule (169, 247, 363, 434). MAVS 
contains an N-terminal CARD-like domain just like RLRs and a C-terminal 
transmembrane domain which defines its mitochondrial localization. Both domains are 
essential for MAVS signaling (363). MAVS also interacts with TRIF, TRAF6, IKKα, 
IKKβ and IKKε, thus leading to the activation of NF-κB and IRF3 (247, 434). Although 
the details of these interactions and activation pathways are still incomplete, available 
data for RLR signaling indicates a schematic picture. Briefly, in the absence of its ligand, 









inactivated form. Binding of dsRNA or 5’ppp-RNA to the basic cleft in the C-terminal 
domain (CTD) induces a conformational change, which causes uncovering of the CARD 
domain in the presence of ATP (389). TRIM25, a member of the tripartite motif (TRIM) 
protein family, is an ubiquitin E3 ligase reported to bind to the N-terminal CARD of 
RIG-I and conjugate the lysine 172 in the internal CARD with a lysine 63-linked 
polyubiquitin chain (86, 322). Then, the CARD domain of RIG-I interacts with the 
CARD domain of MAVS, which causes the conversion of MAVS on the mitochondrial 
membrane to a prion-like aggregate (128). MAVS then activates the cytosolic kinases 
IKKs and TBK1, which activate the transcription factors NF-κB and IRF3. Finally, type I 
interferons and cytokines are induced (238). A schematic illustration of RIG-I mediated 
IFN induction is shown as Fig. 2.2.  
In this RLRs-MAVS-IRF3/7 axis, another study identified that receptor-
interacting serine-threonine kinase 1(RIP1) and Fas-associated death domain (FADD) are 
involved in the TLR-independent innate immune pathway. Both RIP1and TBK1 are 
required for the activation of the transcription factor IRF3 (22). Moreover, lysine-63 
(K63) polyubiquitin chain-mediated ubiquitination of TRAF6 and TBK1 is also required 
for the activation of TRAF6 and TBK1 (59, 403). 
Viral antagonism of IFN induction 
Antagonism via direct interaction with host molecules in the IFN induction pathway  
It is well-known that viruses employ multiple strategies to evade host TLR and 
RLR mediated signaling. Some viral proteins can directly interact with host signaling 





able to interact with RIG-I to block downstream signaling (249). The V protein of 
paramyxoviruses binds MDA5 to inhibit the downstream activation (14). Respiratory 
syncytial virus (RSV) NS1 protein associates with MAVS during early infection to 
disrupt the RIG-I and MAVS interaction as well as downstream signaling (38). The 
γ134.5 protein of HSV forms a complex with TBK1 and disrupts the interaction of TBK1 
and IRF3, which prevents the induction of interferons (418). The Ebola virus protein 
VP35 interacts with IKKε and TBK-1 to impair the activation of IRF3 (300). Human 
papillomavirus 16 (HPV16) E6 oncoprotein binds to IRF3 and inhibits its transcriptional 
activity as well (328). 
Antagonism via degradation or cleavage of host molecules in the IFN induction pathway 
On the other hand, viruses can encode proteins that target host molecules to 
degrade or be cleaved as another way to inhibit the activation of IFN-β. For example, 
viral-encoded 3C protease by encephalomyocarditis virus (EMCV) induces RIG-I 
degradation during EMCV infection (280). MDA5 protein is degraded in poliovirus-
infected cells in a proteasome and caspase-dependent manner (24). HCV protease 
NS3/4A cleaves MAVS to evade innate immunity (206). The 3Cpro cysteine protease of 
coxsackievirus B3 (CVB3) cleaves both MAVS and TRIF to escape host immunity (260). 
CSFV Npro induces the proteasomal degradation of IRF3 (27).  
Antagonism IFN induction via inhibiting IRF3 activation or function  
As a key transcription factor, IRF3 is a frequent target of viral proteins to inhibit 
its phosphorylation, such as HCV NS3/4A protease and PRRSV nsp1β (32, 84). Hepatitis 
A virus and hepatitis B virus suppress IRF3 activation and nuclear translocation as well 





phosphorylation (361). IRF3 can be inhibited by viral coded homologues vIRF3 from 
Kaposi’s sarcoma-associated herpesvirus (KSHV) (137). vIRF3 have been shown to 
interact directly with cellular IRF3 (137). Furthermore, immediate early ICP0 protein 
from herpes simplex virus (HSV) can recruit activated IRF3 and CBP/p300 to ICP0 
nuclear foci to block IFN-β induction (243). 
Antagonism of IFN induction via virally-encoded deubiquitinases  
Recently, the connection between ubiquitination and activation of the IFN 
induction pathway was defined, and cellular and viral deubiquitinases have been 
demonstrated to play a negative role in IFN induction (216, 231, 448). Cysteine proteases 
represent a large family of deubiquitinases (13), which implies that viral-encoded 
cysteine proteases can function as deubiquitinases to inhibit ubiquitination-dependent 
activation of host IFN signaling. Evidence from virus studies indicates that viral-encoded 
cysteine proteases indeed possess deubiquitinase function and inhibit host innate 
immunity, such as arterivirus papain-like protease 2 (415), the PCP domain of PRRSV 
(199, 380) and the leader proteinase of foot-and-mouth disease virus (FMDV) (422). 
Furthermore, as an ubiquitin homologue, small ubiquitin-related modifiers (SUMO) 
cause the sumoylation of IRF3 and IRF7, which has been demonstrated as a means of 
negative regulation of IFN induction by viruses (182). 
Antagonism via viral homologues of host molecules 
Viruses can encode some homologues of the host TLR and RLR signaling 
molecules or related molecules to interfere with host signaling, especially for some DNA 
viruses with a larger genome. For example, vaccinia A46R and A52R, which share amino 





KSHV encodes four homologs of IRFs, vIRF1–4, which inhibit the activity of their 
cellular counterparts. vIRF1, 2, and 3 have been shown to interact directly with cellular 
IRFs (137). 
Other functions of TLRs and RLRs 
TLRs and RLRs form the most important sensor families for viral infection, 
resulting in an innate immune response within minutes of infection to produce type I 
IFNs and pro-inflammatory cytokines. For TLRs, besides their important roles played in 
host innate immunity, TLR mediated signaling is involved in many other biological 
processes. TLRs have also been shown to be an important linker between innate and 
adaptive immunity through their presence in dendritic cells (DCs) (113). TLR activation 
in DCs causes an enhanced display of MHC peptide ligands for T cell recognition. TLR 
activation can also up-regulate co-stimulatory molecules that are important for T cell 
clonal expansion and the secretion of immunomodulatory cytokines to direct T cell 
differentiation into effectors (318). TLRs are able to regulate neutrophil migration, 
activation and apoptosis (335). TLR signals also regulate B-cell activation and survival 
(92). Due to their unique feature linking innate and adaptive immunity via DCs, 
considerable effort has been made to testing TLR ligands as novel vaccine adjuvants to 
enhance the efficacy of vaccination.  
TLRs also play important roles in some diseases and are regarded as potential 
therapeutic targets. It was demonstrated that TLR4 plays a crucial role in the 
development of contact allergy to nickel (352). The application of a TLR4 antagonist in 
the treatment of severe sepsis has entered into clinical trial as well (398). Moreover, 





intestinal function (1), and TLRs are also able to modulate adult hippocampal 
neurogenesis (327). Activation of TLR3 is required for efficient nuclear reprogramming 
during the generation of induced pluripotent stem cells (iPSCs) (190). 
For RLRs, other than its ability to initiate an innate response, RIG-I has been 
proposed to participate in a variety of intracellular events. ATRA-induced differentiation 
and normal myelopoiesis are accompanied by the induction of RIG-I (215, 236).  
Conversely, disruption of the RIG-I in mice leads to the development of a progressive 
myeloproliferative disorder (451). It has been suggested that RLRs also participate in cell 
differentiation, and RIG-I participates in TLR-stimulated phagocytosis (215). In vivo 
studies and work in clinical samples suggest that RIG-I may be involved in immune 
responses associated with both non-infectious and infectious diseases, such as 
atherosclerosis, psoriasis and rheumatoid arthritis (236). 
Taken together, TLRs and RLRs play crucial roles both in immunity and non-
immune events. As IFNs are the key consequence of TLR and RLR activation, IFNs 
induce the synthesis of proteins with antiviral activity. In the next chapter, IFN signaling 





Chapter 3: Interferon Signaling and Function 
Introduction 
IFNs activate cells to establish an antiviral state that is characterized by the 
expression and antiviral activity of IFN-stimulated genes (ISGs) (163). More than 300 
ISGs can be upregulated by IFNs (60). Those ISGs include antiviral effectors, such as 
ISG15 (an IFN-stimulated protein of 15 kDa), the GTPase MX1 (myxovirus resistance 1), 
ribonuclease L (RNaseL) and protein kinase R (PKR). The major signaling pathway 
results in ISG expression is JAK/STAT (Janus kinase and signal transducer and activator 
of transcription) pathway (346). There are other pathways involved in IFN-mediated 
signaling as well, such as the MAPK-p38 pathway and the phosphatidylinositol 3-kinase 
(PI3 kinase) pathway (296). In this chapter, the classical JAK/STAT pathway in type I 
IFN signaling and the effectors of IFNs for their antiviral functions are reviewed in detail. 
Discovery of IFN-mediated signaling 
The concept that individual cytokines or peptides bound to specific cell surface 
receptors cause the transcription of specific sets of genes was established 30 years after 
the initial definition of IFNs (196, 373). The study of IFNs started to focus on what kind 
of genes would be upregulated by IFNs. Early studies indeed demonstrated that IFN 
binding to distinct cell surface receptors leads to the synthesis of several unique 
polypeptides and their corresponding mRNAs (186). Due to technical limitations, less 
attention was paid to the function of those ISGs during that time. However, by analyzing 
the genomic 5'-flanking regions of the ISG54 and ISG15, an IFN-stimulated response 





treated cell lysate, a cellular factor (named ISGF3) was identified as well 
(196). Subsequent studies revealed that ISGF3 consisted of four pre-existing proteins in a 
large complex with sizes of 48, 84, 91 and 113 kDa for each protein. Three of those 
proteins with sizes of 91, 84 and 113 kDa were suggested to come from the same protein 
family and are currently known as STAT1α, STAT1β and STAT2, respectively. The 48 
kDa protein was later confirmed as IRF9, belonging to the interferon regulator factor 
(IRF) family (416). STAT1α and STAT1β have different sizes of 91 and 84 kDa due to 
alternative splicing of the same gene product (368). STAT1β, which lacks the 38 C-
terminal residues, including the Ser727 site and most of the C-terminal transactivation 
domain (TAD), is believed to serve as a negative regulator (368). Since that time, more 
details about the STAT family have been revealed, and different signaling pathways for 
type I IFNs and type II IFN have been discovered. The IFN-γ specific promoter (GAS, 
gamma IFN-activated sequence), with a different sequence from the ISRE and another 
factor, only contains STAT1 bound to this promoter (GAF, gamma IFN activated factor) 
(57, 197). Further studies have demonstrated the involvement of a kinase in IFN-α 
induced ISGF3 formation and ISG expression, indicating a requirement for kinase 
activity in IFN signaling (316). Additionally, phosphopeptide mapping confirmed that 
STAT1 and STAT2 are phosphorylated at tyrosine (Y) 701 and 690, respectively, in 
response to IFN-α (346, 368). Collectively, this evidence finally led to the formulation of 
the concept of the JAK/STAT pathway. In the next part, the details of the JAK/STAT 



















JAK/STAT pathway  
The JAK/STAT pathway was first characterized in the type I interferon (IFN) 
response (54). Beyond IFN signaling, STAT proteins are critical for signal transmission 
of many different membrane receptors, such as cytokine and hormone receptors (195). 
The JAK/STAT pathway is conserved during eukaryotic evolution. In Drosophila, the 
JAK/STAT pathway is genetically well-characterized and has been shown to be 
important for larval hematopoiesis, sexual identity, embryo segmentation and the 
formation of polarity in the eye (447). JAK/STAT are the transducers of cytokine-
mediated signaling in mammals after cytokines bind to specific cell-surface receptors 
(376).  
There are four members in the JAK family: JAK1 to 3 and tyrosine kinase 2 
(TYK2). They are all characterized by a C-terminal catalytic domain and a related, but 
enzymatically inactive, pseudo-kinase or kinase-like domain (271). They also share five 
additional domains of sequence similarity throughout the N-terminal region (195). All 
those seven domains are now called Janus homology domains (JHD) 1 to 7.  
The STAT family contains seven members: STAT1, 2, 3, 4, 5A, 5B and 6. 
STAT1 contains two isoforms: STAT1α and STAT1β. All STATs except STAT1β share 
a very similar structure: an N-terminal domain (ND), a coiled-coil domain (CCD), a 
DNA-binding domain (DBD), a linker domain (LD), a Src homology 2 (SH2) domain, 
and a transactivation domain (TAD) (376). Generally, JAKs are non-covalently 
associated with the cytoplasmic tail of specific receptors. Upon cytokine binding, 
receptor dimerization or oligomerization leads to JAK apposition and 





Tyrosine phosphorylation by activated JAKs of cytokine-receptor cytoplasmic domains 
then provides binding sites for SH2 domain of the STAT proteins. The STAT proteins are 
then recruited to the JAKs, whereupon they are phosphorylated on a tyrosine residue 
(around residue 700 of their 750–850 aa-long sequence) (195). Depending on the nature 
of the activating ligand, STAT/STAT interactions occur immediately through reciprocal 
SH2 interactions (126). All STAT proteins are able to form homodimers and 
heterodimers depending on the signaling pathway activated by different cytokines (195, 
296).  
STATs transduce signals for a large subfamily of cytokines due to the conserved 
receptor families to which JAKs bind. These cytokine families include the IFN family 
(IFN-α/β, IFN-γ; IL10, IL-19, IL-20, IL-22), the gp130 receptor family (IL-6, IL-11, 
OSM, LIF, CT-1, G-CSF, IL-12, IL-23, leptin, CTNF, NNT-1/BSF-3), the γC family (IL-
2, IL-4, IL-7, IL-9, IL-15, IL-21) and the single chain family (Epo, GH, PRL, Tpo) (345, 
347). STAT1 and STAT2 are the major players involved in type I IFN-mediated 
signaling. The activation of such STATs is a common response to different type I IFNs 
since the same receptor is utilized by those IFNs, thereby activating TYK2 and JAK1. 
Phosphorylated STAT1 and STAT2 form heterodimers, with the further association of 
IRF9 to form the ISGF3 complex. Other complexes induced by type I IFNs include 
STAT1-STAT1, STAT3-STAT3, STAT4-STAT4, STAT5-STAT5 and STAT6-STAT6 
homodimers, as well as STAT1-STAT3, STAT1-STAT4, STAT1-STAT5, STAT2-
STAT3 and STAT5-STAT6 heterodimers (296). On the other hand, type II IFN activates 
JAK1 and JAK2 and results in the phosphorylation of STAT1 on the tyrosine residue at 





which translocates to the nucleus and binds to GAS elements to initiate transcription 
(296). Karyopherin α1 (KPNA1) is the essential importin for the nuclear transport of 
phosphorylated STAT1 (358). However, the interaction of STAT1 and KPNA1 does not 
appear to be involved in the “classical nuclear localization signal (NLS)” recognition 
(358). Additionally, STAT1 possesses a non-classical NLS and KPNA1 binds between 
two STAT1 monomers, with two major binding determinants in the SH2 and DNA 
binding domains (266).  
For the function of other STATs, STAT3 was initially identified as an IL-6 
dependent transcription factor that promotes acute phase gene expression (9). It is now 
known to transduce signals for the entire IL-6 (IL-6, IL-11, IL-31, LIF, CNTF, CLC/CLF, 
NP, CT1, OSM) and IL-10 (IL-10, IL-19, IL-20, IL-22, IL-24, IL-26) families, as well as 
granulocyte colony stimulating factor (G-CSF), leptin, IL-21 and IL-27 (173). Recently, 
STAT3 was implicated for its involvement in transformation. It has been demonstrated 
that STAT3 is constitutively active in some murine and human tumors, and is able to 
regulate the Src-dependent transformation of fibroblasts (37).  
STAT4 was initially identified through screens for STAT homologues and found 
to share 52% identical amino acids to STAT1 (436). Unlike STAT1, neither IFN-α nor 
IFN-γ activate STAT4 (436). The expression of STAT4 was found to be limited to 
myeloid cells, NK cells, dendritic cells and T lymphocytes (436, 458). Subsequent studies 
determined that STAT4 is activated by IL-12, which plays a critical role in the 
development of the Th1 subset of T helper cells (21, 173).  
STAT5A and STAT5B were found to be encoded by two linked genes, STAT5a 





STAT5 was originally identified as mammary gland factor (MGF), which is the central 
mediator in the lactogenic hormone response in mammary epithelial cells (419). In 
addition to be a prolactin-induced transcription factor, STAT5 proteins are activated by 
the IL-3 family (IL-3, IL-5 and GM-CSF), the IL-2 family (IL-2, IL-7, TSLP, IL-9, IL-15 
and IL-21), growth hormone (GH), Epo and Tpo (173). STAT5A and STAT5B display 
functional redundancy. Despite these structural and functional similarities, STAT5A 
single knockout mice are predominately defective in prolactin (RPL) dependent 
mammary gland development, while STAT5B single knockout mice exhibit defects 
similar to GH receptor deficient mice (173). STAT5 can also act as an oncogene and was 
found to be constitutively phosphorylated in cancer cells (267).  
STAT6 was originally identified from cell extracts as the IL-4 stimulated STAT 
and it was soon shown to be also activated by IL-13 as well as to the common receptor 
chain shared by IL-4 and IL-13 (129, 210). As mediator for IL-4 and IL-13 signaling, 
STAT6 plays an important role in regulating acquired immunity since IL-4 is secreted by 
activated T and B lymphocytes, mast cells and basophils and promotes the activation of 
several cell types, most notably Th2 cells (173). 
Functions of ISGs 
The binding of type I IFNs to their receptors on the cell surface initiates the 
signaling cascade, which leads to the induction of more than 300 ISGs. Some of these 
ISGs can be upregulated by type II IFNs as well (55, 60). The functional diversity of 
ISGs indicates that IFNs play multiple roles in the host beyond their anti-viral or anti-
tumor function. Evidence from microarray studies have also confirmed that the 





that are commonly expressed (355). This implies that IFNs can also have different 
functions in different cells. ISGs can be further classified into different categories 
according their functions. Depending on the category, ISGs are involved in many distinct 
pathways, such as amino acid and lipid metabolism, antigen processing and presentation, 
host cell signaling, transcriptional regulation, ubiquitination, apoptosis, host defense, 
immune modulation, inflammation and tumor suppression (55). 
The ISGs can be divided into at least two large groups based on their major 
functions. The first group is proteins involved in host defense, including proteins directly 
possessing antiviral activity at the cellular level, as well as immunomodulatory genes 
including cytokines and chemokines, which recruit lymphocytes to sites of inflammation 
or infection (55). There are also genes in this group that promote lymphocyte adhesion to 
endothelial cells, such as ICAM1, SELL and CD47. Adhesion of lymphocytes to vessel 
walls is an important first step in the trafficking of lymphocytes to areas of infection (55).  
The second large group of ISGs includes genes involved in host signaling. In this 
group, there are PRRs, such as TLRs and RLRs, which detect pathogens and initiate the 
signaling of the host innate response. Some adaptor proteins for TLRs that mediate 
signaling, such as MyD88, can be upregulated as well to enhance PRR signaling (189). 
There are also transcription factors, such as members of the IRF family, the STAT family 
and NF-κB, which form amplification loops, resulting in increased IFN production or 
ISG expression (55, 189, 336). Moreover, some proteins that are involved in other 
pathways can be upregulated as well, such as genes of ubiquitin activating E1 and 





and tumor suppression functions. There are indeed some ISGs classified as proteins 
involved in apoptosis and tumor suppression (189). 
Mechanisms of antiviral ISGs 
Among all the ISGs, the most important ones for viral infection are those 
molecules possessing antiviral activity as the effectors of IFNs, such as ISG15, MX1, the 
2'-5' oligoadenylate synthetase (OAS) family, RNaseL, PKR and ISG56 or the IFIT1 
family. In this section, each of these ISGs will be discussed. 
ISG15 
ISG15 was identified soon after the discovery of ubiquitin, and was recognized as 
an ubiquitin homologue (219). As an ubiquitin-like molecule, ISG15 can be conjugated to 
protein substrates; this process is called ISGylation, and is reversible. However, 
ISGylation does not result in the degradation of the substrates as K48-linked 
ubiquitination, but instead parallels the activating effects of K63-linked ubiquitination 
(336). ISG15 has been reported to interfere with Ub-E2 and E3 interactions to inhibit 
protein ubiquitination (228), and can also prevent virus-mediated degradation of IRF3 to 
increase the induction of IFN-β expression (221). Besides, ISGylation has also been 
shown to modulate the function of enzymes. As an example, the conjugation of ISG15 to 
protein phosphatase 1B (PPM1B) suppresses its activity and enhances NF-κB signaling 
(392). Moreover, mice deficient in ISG15 show increased susceptibility to influenza A 






In addition to components of the ISGylation pathway, IFNs induce the expression 
of several guanine-hydrolyzing proteins such as MX proteins. MX1 and MX2 were first 
identified as antiviral proteins by the observation that mutations within the MX locus on 
chromosome 16 confer susceptibility to orthomyxovirus infection in mice (19). Two 
human homologues, MXA and MXB, have been identified as well. MX proteins can 
target viral nucleocapsid-like structures (174). 
The smooth endoplasmic reticulum localization of MXs allows them to screen 
exocytic events and mediate vesicle trafficking to trap essential viral components, and 
therefore, prevent viral replication at early time points (2). Furthermore, MX1 can 
associate with subunits of the influenza virus polymerase to block viral gene transcription 
(404). 
OAS1 and RNaseL 
The OAS protein family and RNaseL are another two important ISGs. The OAS 
family and RNase L are functionally related. The OAS proteins are unique in their 
capacity to synthesize 2' to 5' linked phosphodiester bonds to polymerize ATP into 
oligomers of adenosine (314). These unique 2',5'-oligomers specifically activate the latent 
form of RNaseL, which can then mediate RNA degradation (229). RNA degraded by 







PKR is another important ISG that belongs to a small family of protein kinases 
responding to environmental stresses to regulate protein synthesis (324). PKR is 
constitutively expressed in all tissues at a basal level and is upregulated by IFNs. Under 
normal circumstances, PKR is maintained as an inactive monomer. This repression is 
released by activating ligands, such as viral RNAs, which elicit a conformational change 
and result in the activation of PKR. The active PKR enzyme consists of a homodimer 
with autophosphorylation at several key residues (336). Activation of PKR following 
dimerization leads to the phosphorylation of initiation factor eIF2α to halt translation. 
ISG56 
The ISG56/IFIT1 family is comprised of four members, ISG56/IFIT1, 
ISG54/IFIT2, ISG60/IFIT3 and ISG58/IFIT5, whose homologs are evolutionarily 
conserved (80). ISG56 expression is extraordinarily responsive to not only IFN treatment 
but also to certain viral and bacterial molecular patterns. ISG56 family members can 
inhibit translation by binding to specific subunits of eIF3, presenting a mechanism of 
inhibition distinct from PKR and OAS (80). Translation of the hepatitis C virus (HCV) 
positive-sense RNA genome is initiated by IRES-dependent ribosome recruitment, which 
is different from cap-dependent translation, and can be compromised in the presence of 
ISG56 (224, 421). For translation-unrelated inhibition, human ISG56 can directly bind 
the E1 helicase of human papillomavirus (HPV) to sequester the E1 helicase in the 
cytoplasm, separating it from the viral genome in the nucleus (396). Furthermore, ISG56 
can also act as a negative feedback regulator to dampen virus-induced innate immune 





some RNAs, such as adenylate uridylate (AU)-rich RNAs, with or without a 5' PPP, 
suggesting a new mechanism underlying the antiviral activity of this ISG family (439). 
Viperin 
Viperin (also known as cig5 and RSAD2) is a highly conserved, 361-amino-acid 
protein with a molecular mass of 42 kDa (112). It was first identified as a human 
cytomegalovirus (HCMV)-inducible gene in fibroblasts that was renamed viperin (for 
virus inhibitory protein, endoplasmic reticulum (ER) associated, interferon inducible). 
Viperin was first shown to be antiviral against HCMV. Overexpression of viperin in 
human fibroblasts prior to HCMV infection was found to significantly decrease the 
expression of the late viral proteins such as gB, pp28 and pp651(45). Since then, viperin 
has been demonstrated to have antiviral activity against a broad range of viruses from 
both DNA and RNA viral families, such as CMV, RSV, DENV, influenza A and HIV 
(112). Viperin had been shown to inhibit influenza A and HIV-1 via blocking viral 
particle release (112). It also regulates cellular lipid metabolism during HCMV infection 
(362). However, the full details of the antiviral mechanisms of viperin remain unknown 
and need further investigation. 
PML protein 
PML (promyelocytic leukemia protein) protein is an ISG as well, containing both 
an IFN-stimulated response element and a gamma-activated site, meaning its expression 
is responsive to both type I IFNs and type II IFN, respectively (375). PML mediates 
PML-nuclear body (PML-NB) formation, generating electron-dense nuclear punctate 
areas within the intrachromosomal regions of the nucleus (46). The integrity of these 





as a tumor suppressor (340). In addition to these processes, PML-NBs have been 
implicated in multiple cellular responses, including apoptosis, DNA damage repair, the 
cellular stress response, transcriptional regulation, antiviral defense and post-translational 
modifications (411). 
Viral interference of IFN-activated JAK/STAT signaling 
As IFN signaling induces the expression of ISGs to inhibit virus replication, 
viruses employ different strategies to antagonize IFN-activated JAK/STAT signaling to 
facilitate their replication. Viruses can target different stages of the JAK/STAT pathway 
to inhibit signaling. All flaviviruses examined thus far, including the West Nile virus, 
Japanese encephalitis virus, Langat virus and Dengue virus (DENV), can suppress 
JAK/STAT signaling by inhibiting JAK phosphorylation (31, 102, 119, 211). This blocks 
downstream phosphorylation of STAT1 and STAT2. The hepatitis C virus proteins 
phosphatase 2A and NS5A disrupt STAT1 phosphorylation and suppress type I interferon 
signaling (184, 364). Rotavirus NSP1 inhibits interferon-mediated STAT1 
phosphorylation as well (360).  
Besides STAT1 phosphorylation, STAT degradation is also a common 
mechanism of viral IFN antagonism. The V protein of human parainfluenza virus 2 can 
lead to the proteolytic degradation of STAT1 and STAT2 (15, 281, 298, 299). The 
activity of DENV NS5 protein can also mediate STAT2 degradation (20). HCV also 
targets the interferon-α-activated JAK/STAT pathway by promoting proteasome-
mediated degradation of STAT1 and STAT3 in immune cells and hepatocytes (377). 
Nuclear translocation of STAT1 is another antagonizing target for viruses. VP24 





proteins, thereby preventing them from transporting tyrosine-phosphorylated STAT1 to 
the nucleus (317). PRRSV nsp1β is able to induce ubiquitin-mediated degradation of 
KPNA1 to inhibit nuclear translocation of the ISGF3 complex (284, 424). The 3Cpro of 
FMDV contributes to the degradation of KPNA1 and thus blocks STAT1/STAT2 nuclear 
translocation as well (66). 
Moreover, activation of the JAK/STAT pathway can be regulated by suppressors 
of cytokine signaling (SOCS) proteins (8), as SOCS proteins negatively regulate 
signaling pathways by facilitating ubiquitination and proteasome degradation of signaling 
molecules (8). However, viruses have also developed strategies to induce robust SOCS 
protein expression, which essentially “hijack” SOCS function to promote virus 
replication. These viruses include HIV-1, HBV, HCV, HSV1, RSV, Ebola virus, 
influenza A virus and coxsackievirus (8). 
Summary  
The IFNs are responsible for inducing expression of a large group of ISGs, which 
play roles in host resistance to viral infections and activate key components of the 
adaptive immune system, including antigen presentation, activation of T cells, B cells, 
and natural killer cells. IFNs activate signaling via an evolutionally conserved 
JAK/STAT pathway, which transduces signals from other cytokines as well. Though the 
induction and signaling of IFNs are well-defined and antagonism of many viruses are 
known, further studies are needed to address how viruses regulate IFN induction and 
signaling to facilitate their replication and pathogenesis in vivo. On the other hand, 
elucidation of ISG functions is also interesting as most ISGs are not well-defined, though 





ISGs in antiviral responses make it difficult to tease apart the functions of individual 
ISGs. In the coming decade, we expect more data will be available to increase our 




















Chapter 4: Hepatitis E Virus Inhibits Type I Interferon Induction  
ABSTRACT 
HEV causes both endemic and epidemic human hepatitis by fecal-oral 
transmission in many parts of the world. Zoonotic transmission of HEV from animals to 
human has been reported. Due to the lack of an efficient cell culture system, the 
molecular mechanisms for HEV infection remain largely unknown. In this study, we 
found that HEV replication in hepatoma cells inhibited polyIC-induced IFN-β expression 
and that HEV ORF1 product was responsible for this inhibition. Two putative domains, 
X and the papain-like cysteine protease domain (PCP), from HEV ORF1 were identified 
as the IFN antagonists. When overexpressed in HEK293T cells, the X domain (or Macro 
domain) inhibited polyIC-induced phosphorylation of IRF3, which is the key 
transcription factor for IFN induction. The PCP domain was shown to have 
deubiquitinase activity for both RIG-I and TBK-1, whose ubiquitination is a key step in 
their activation in polyIC-induced IFN induction.  Furthermore, replication of a HEV 
replicon containing GFP (E2-GFP) in hepatoma cells led to impaired phosphorylation of 
IRF3 and ubiquitination of RIG-I and TBK-1, which confirmed our observations of X 
and PCP inhibitory effects in HEK293T cells. Taken together, our study identified the 
IFN antagonists within the HEV ORF1 polyprotein and expanded our understanding of 








      Hepatitis E Virus is a fecal-oral transmitted viral pathogen, which causes 
acute hepatitis with a mortality rate at or  below 3% in young adults and to up 30% in 
pregnant women in the third trimester (151, 171). While previously thought as a public 
health problem only for developing countries, hepatitis E has now been recognized 
frequently in industrialized countries (171). Isolation of HEV from the pig, chicken, 
mongoose, rabbit, rat, ferret, bat, fish and deer has been reported (105, 202, 246). 
Zoonotic transmission of HEV from animals to human has been documented (171), and is 
considered as a major transmission route for sporadic cases in the industrialized countries.  
   HEV contains a 7.2 kb single-stranded positive-sense RNA genome, which is 
capped and poly-adenylated (74). It has been classified as the sole member of the genus 
Hepevirus, family Hepeviridae (74, 151).  There are four major genotypes and a single 
known serotype for HEV (105, 252). There are three ORFs in the HEV genome (393).  
ORF1 encodes a polyprotein that has all non-structural proteins needed for HEV 
replication. ORF2 encodes the capsid protein of HEV virion. ORF3 encodes a small 
multifunctional protein with a molecular weight of 13 kDa (vp13).  
As an invader, HEV faces host innate immune responses, which are mainly 
induced by activation of host pattern recognition receptors.  For recognition of RNA 
viruses, those receptors include RLRs and TLRs. Stimulation of the RLR and TLR 
signaling pathways leads to activation of transcription factors such as IRF3, IRF7 and 
NF-κB. These transcription factors mediate expression of type I IFNs and inflammatory 
cytokines, which not only lead to an antiviral state of the neighboring uninfected cells, 





evolved many strategies to evade from host innate immune responses. Little is known 
about how HEV evades from host IFN induction. Microarray analysis from Hepatitis C 
virus (HCV) and HEV-infected chimpanzees showed that HEV evoked a lower 
magnitude of IFN response than HCV, indicating that HEV must employ an effective 
strategy to dampen host innate immune responses (443).  
The objective of this study was to elucidate the mechanism of HEV interference 
with type I IFN induction. We found that HEV replication in S10-3 hepatoma cells 
inhibited IFN-β induction stimulated by polyIC, a dsRNA homologue. Further studies 
identified two putative domains (X and PCP) from ORF1 to be the IFN antagonists. The 
X domain (also known as Macro domain) inhibited polyIC-induced IRF3 
phosphorylation while the PCP led to deubiquitination of both RIG-I and TBK-1. These 
findings were also confirmed in hepatoma cells with HEV replication. Our findings 
provide valuable information about function of the HEV ORF1 product and improve our 





MATERIALS AND METHODS 
Cells, transfection, viruses and chemicals. HEK293T and HEK293 cells were 
maintained in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% 
fetal bovine serum (FBS). S10-3 cells, a subclone of Huh-7 hepatoma cells (99),  were 
maintained in DMEM-Reduced Serum (DMEM-RS) medium supplemented with 3% 
FBS. Transfection of HEK293T and HEK293 cells with plasmid DNA was performed by 
using FuGeneHD (Promega, Madison, WI), according to the instructions of the 
manufacturer.  
Full-length RNAs of HEV and HEV-GFP were obtained by in vitro transcription 
from plasmids pSK-E2 and pSK-E2-GFP (71), respectively, using AmpliCap-Max T7 
High Yield Message Maker Kit (Cellscript, Madison, WI). Transfection of S10-3 cells 
with RNA was performed using an optimized protocol with DMRIE-C reagent 
(Invitrogen, Grand Island, NY). Briefly, after S10-3 cells reaching 70% confluence in a 
12-well plate, medium was discarded and the monolayer cells were washed twice with 
PBS pH7.4, followed by addition of 0.5 mL serum-free Opti-MEM to each well.  For 
each well, 1 µg RNA was add to 50 µL Opti-MEM and mixed evenly with 4 µL DMRIE-
C. After incubation under room temperature for 20 minutes, the mixture was added to the 
S10-3 cells. One mL DMEM-RS with 3% FBS was added to each well 5 h post 
transfection. The cells were cultured at 34.5ᵒC. 
HEK293 cells stably expressing VenusC1-IRF3 (HEK293-IRF3) were established 
by transfection of the cells with VenusC1-IRF3 and selection under antibiotic G418. The 





Polyinosinic-polycytidylic acid (polyIC, LMW), a synthetic analog of double-
stranded RNA (dsRNA) (Invivogen, San Diego, CA) was used to induce interferon 
production. The HEK293T and S10-3 cells were transfected with the polyIC at a 
concentration of 1 µg/ml and incubated for 12 h before harvested for further analysis.   
Plasmids. Putative ORF1 domains were PCR amplified and cloned to vector 
pCAGEN (Addgene plasmid# 11160) with HA-tag at N-terminus as previously reported 
(235, 424). VenusC1-IRF3 was constructed in house by subcloning IRF3 from pFLAG-
CMV-IRF3 (a gift from Dr. Michael Gale Jr.). Full length RIG-I cDNA from S10-3 cell 
RNA was cloned into KpnI site in pCMV-Flag-MAT-Tag-1 vector (Sigma). All primers 
used for plasmid construction in this chapter were listed in Table 4.1. All in house 
constructed plasmids were subjected to DNA sequencing to confirm the inserts.  
HEV replicons: pSK-E2 and pSK-E2-GFP were described previously (71, 75, 97). 
Construction of Myc-RIG-I(N) (87), Myc-IPS1 (220), MDA5(N) (441), FLAG-TBK-1 
(399), and FLAG-IKKε (293) plasmids were previously described.  
Immunofluorescence assay (IFA) An immunofluorescence assay (IFA) was 
carried out as previously reported (154),  by using chimpanzee antibody against the HEV 
capsid protein. Specific antibody-capsid reactions were detected by DyLight 549 goat 
anti-human immunoglobulin (Ig) G conjugate (Rockland Immunologicals, Gilbertsville, 
PA). The coverglass was mounted onto slide using SlowFade Gold antifade reagent 
containing 4’6’-diamidino-2-phenylinodole (DAPI) (Invitrogen) and observed using 
fluorescence microscopy.  
Western blot analysis. Cells were lysed in the Laemmli sample buffer. The 





electrophoresis (SDS-PAGE) and Western blot as previously described (154, 455). 
Antibodies against GFP (Santa Cruz Biotechnology, Santa Cruz, CA), phos-IRF3-S396 
(Cell Signaling Technology, Danvers, MA), HA (Thermo Fisher Scientific, Waltham, 
MA), IRF3 (Santa Cruz) and tubulin (Sigma-Aldrich, St. Louis, MO) were used in the 
blotting. The chemiluminescence signal was recorded digitally using a ChemiDoc XRS 
imaging system (Bio-Rad Laboratories, Hercules, CA). Digital signal acquisition and 
densitometry analyses were conducted using the Quantity One Program, Version 4.6 
(Bio-Rad).  
Reverse transcription and real-time PCR (RT-qPCR). Total RNA was isolated 
from cells with TRIzol® Reagent (Invitrogen). RNase-free DNase was used to remove 
carryover DNA from the RNA isolation procedure. Reverse transcription using AMV 
reverse transcriptase was conducted along with oligo dT and random 15-mer. Real-time 
PCR with SYBR Green detection (Invitrogen) for IFN-β was done as described 
previously (285). Transcripts of RPL32 (ribosomal protein L32) were also detected from 
the same samples to serve as an internal control for normalization. Gene expression was 
quantified by 2-∆∆CT method (218). Primers of IFN-β and RPL32 were described 
previously (265). 
Ubiquitination Assay. Immunoprecipitation (IP) was conducted as previously 
described (284, 424) with modifications. Briefly, S10-3 and HEK293T cells were lysed 
with a lysis buffer (50mM Tris pH 7.4, 150 mM NaCl, 0.2 mM EDTA, 2 mM EGTA, 0.5% 
IGEPAL CA-630, 10% glycerol, 1 mM sodium vanadate) as described previously (424), 
with the supplement of a protease inhibitor cocktail (Sigma) as recommended by the 





The lysate was clarified by centrifugation at 14000 xg for 5 min at 4ºC. Antibodies 
against RIG-I or TBK-1 were added to the supernatant. IP with protein G agarose (KPL 
Inc, Gaithersburg, MD) was done following the manufacturer’s instructions. The IP 
samples were subjected to immunoblot analysis with antibody against ubiquitin. 
Reporter assay. HEK293T cells were transfected with the reporter pGL3.0-IFN-
β promoter, and testing plasmids. Renilla vector pRL-TK (Promega) was also transfected 
for normalization. At 48 h after transfection, the cells were lysed for luciferase activity 
assay of Firefly and Renilla luciferases, respectively, by following manufacturer’s 
instructions (Promega). Lysate of cells transfected with empty vector of testing plasmids 
was used as a control for calculation of IFN-β promoter activation level. Relative fold of 
luciferase activity is shown.  
Statistical analysis. Differences in indicators between treatment samples, such as 
IFN-β mRNA level between the group in the presence of HEV replication and the control 








HEV replication inhibits IFN-β expression induced by polyIC transfection 
We first tested whether HEV replication would interfere with interferon 
induction. S10-3 cells, a subclone of Huh-7 cells that is more susceptible to transfection 
with whole HEV genomic RNA (369), were used. HEV genomic RNA was transcribed 
from pSK-E2 plasmid containing whole cDNA of Sar55 (genotype I) HEV genome, as 
previously described (71). Full length HEV RNA generated from the  pSKE2-GFP 
construct, in which insertion of GFP disrupts expression of ORFs 2 and 3 (71), was 
included for comparison. S10-3 cells were transfected with the two different HEV RNAs. 
HEV replication was detected by immunofluorescence assay with HEV antibody (Fig. 
4.1A). The cells were transfected with polyIC 10 days post-HEV RNA transfection to 
stimulate IFN production. RT-qPCR was then conducted to detect IFN-β transcript. 
Compared with uninfected cells, S10-3 cells with HEV replication (from pSK-E2 RNA) 
had significantly lower level of IFN-β transcript by 3.2-fold (Fig. 4.1B), which indicates 
that HEV replication reduced IFN expression evoked by polyIC. Similarly, the cells 
transfected with RNA from pSKE2-GFP had significantly lower level of IFN-β transcript 
by 4.8-fold. This result suggests that ORF1 product was at least partially responsible for 














 HEV ORF1 product inhibits IFN production  
After finding that the inhibition of IFN induction was potentially due to the ORF1 
product, we cloned 6 fragments of ORF1 into pCAGEN plasmid with HA tag at N 
terminus according to a previous analysis of the putative domains (179) (Fig. 4.2A). They 
were methyltransferase domain (Met); Y domain (Y); papain-like cysteine protease 
(PCP); a fragment covering hypervariable region, proline-rich domain and X-domain 
(HPX); helicase (Hel); and RNA-dependent RNA polymerase (RdRp). Protein expression 
of these HA-tagged fragments in HEK293T cells transfected with these plasmids was 
confirmed with Western blotting using HA antibody (Fig. 4.2B). All the proteins except 
HPX appeared to be one band. The HPX lane had two bands, indicating an excision of 
the product.  
 
Fig. 4.1 HEV replication in S10-3 cells reduces IFN production induced by 
polyIC. 
A. HEV replication in S10-3 cells detected by immunofluorescence assay. The cells were 
transfected with full length HEV genomic RNA from pSK-E2. Red fluorescence on the left 
panel indicates HEV ORF2 protein. Nuclear DNA shown on the right panel was counterstained 
using DPAI. B. Reduction of IFN-β expression in HEV-infected S-10 cells detected by real 
time RT-PCR. The cells were transfected with polyIC (PIC). Relative folds of IFN-β mRNA 
level in comparison to control cells without HEV RNA transfection are shown. Significant 






Next we examined their effects on IFN expression in HEK293T cells. Empty 
vector and PRRSV nsp1β, which is known to inhibit IFN induction (32), were included 
as controls.  At 48 h after the transfection, the cells were transfected with polyIC to 
stimulate IFN induction. RT-qPCR was conducted to detect IFN-β mRNA level. 
Compared with the cells transfected with empty vector, PCP and HPX led to a significant 
reduction of IFN-β expression by 2.6 and 7.6-fold, respectively (Fig. 4. 2C). Likewise, 
PRRSV nsp1β led to 4.6-fold reduction. However the other fragments of ORF1 did not 
have an inhibitory effect on IFN-b induction, indicating that ORF1 PCP and HPX were 
IFN antagonists. 
HEV X domain inhibits IFN induction via blocking phosphorylation of IRF3 
 After finding the two ORF1 products inhibit IFN induction, we selected HPX to 
determine its interference mechanism first. HEK293T cells were transfected with 
plasmids encoding the IFN-β reporter, HPX, and specific component of the RIG-I 
signaling pathway, specifically RIG-I(N-terminal domain), MDA5(N-terminal domain), 
TBK-1  or IKKε. Compared with cells transfected with empty vector, HPX expression 
resulted in a significant reduction of RIG-I and MDA5-induced IFN-β reporter 
expression by 1.8 and 2.2-fold, respectively (Fig. 4. 3A). Similarly, when the cells were 
transfected with TBK-1 or IKKε plasmid, HPX reduced luciferase yield significantly by 
2.26 and 2.35-fold, respectively (Fig. 4. 3B). PRRSV nsp1β reduced luciferase yield of 
IFN-β reporter, as expected. These results indicated that HPX interfered with IFN 
induction via RLR pathway. 
As HPX inhibits RLR pathway, we tested the activation status of IRF3 in cells 





after polyIC stimulation is hard to detect, we co-transfected the cells with FLAG-IRF3 







polyIC and harvested 8 h later for Western blotting. Compared with cells transfected with 
empty vector, the cells with HPX had much lower level of IRF3 phosphorylation (Fig. 4. 
4A), while the levels of total IRF3 and tubulin were similar between the samples. The 
result indicated that HPX interfered with IRF3 activation. 
The HPX regions contains 3 putative domains. To determine which domain was 
capable of antagonizing IRF3 activation, we cloned the three domains individually into 
pCAGEN expression vector, which encodes an HA tag at the N-terminus. When co- 
Fig. 4.2 Screening of ORF1 products for potential IFN antagonists. 
A. Schematic illustration of ORF1 products. Met: Methyltransferase domain; Y: Y domain; PCP: 
papain-like cysteine protease; HPX: hypervariable region, proline-rich domain and X-domain; Hel: 
helicase; RdRp: RNA-dependent RNA polymerase. The numbers above the boxes indicate numbers 
of amino acids of ORF1 polyprotein. B. Cloning and expression of ORF1 fragments in HEK293T 
cells detected by Western blotting. The fragments were expressed as HA-tagged proteins. C. 
Inhibition of polyIC-induced interferon-β expression by ORF1 fragments in HEK293T cells 
detected by RT-qPCR. The cells were transfected with plasmids of the ORF1 fragments and then 
transfected with polyIC. At 12 h after polyIC treatment, the cells were harvested for RNA isolation 
and real time PCR to detect IFN-β transcript. PRRSV nsp1β was included as a control. Relative 
folds in comparison with untreated control cells are shown. EV: empty vector. Significant 





expressed with FLAG-IRF3 in HEK293T cells, expression of the three small HPX 
domains was very low. However, unexpectedly, FLAG-IRF3 expression was interfered in 






expression was not affected (data not shown). To solve the issue of plasmid interference 
in co-expression, we established HEK293 cells stably expressing VenusC1-IRF3, which 
makes it easy to observe IRF3 expression and select positive clones. Phosphorylation of 
VenusC1-IRF3 after polyIC stimulation in the stable cells in the presence of HV, Pro or 
X domain was examined by Western blotting. The X domain was identified to be the 
inhibitor for IRF3 phosphorylation, while HV and Pro domains had minimum effect (Fig. 
4. 4B).  
Fig. 4.3 Reporter assay showing ORF1 HPX product inhibits IFN-β 
induction 
A. HPX product inhibits RIG-I or MDA5-activated IFN-β induction. HEK293T cells were 
transfected with IFN-β reporter plasmid, along with RIG-I(N) or MDA5(N), and nsp1β or 
HPX DNA. Firefly and renilla luciferase activities were measured at 48 h post transfection. 
PRRSV nsp1β was included as a positive control. EV: empty vector. Significant differences 
from EV control are denoted by “**”, which indicate P < 0.01. B. HPX fragment inhibits 





PCP domain deubiquitinates both RIG-I and TBK-1 
 During our screening for the IFN antagonists from ORF1 domains, the papain-
like cysteine protease domain also inhibited polyIC-induced IFN expression. It was 
reported that HEV Met-PCP polyprotein had deubiquitination activity for ubiquitin, 
SUMO and ISG15-conjugated cellular proteins (157). We reasoned that PCP could 
potentially lead to deubiquitination of both RIG-I and TBK-1 as ubiquitination of these 
two molecules is essential for their activation (226). To test this, we co-transfected 293T 
cells with plasmids expressing PCP and RIG-I or TBK-1, since the levels of endogenous 
RIG-I and TBK-1 are too low to be detected in Western blotting. Samples were 
immunoprecipitated with antibodies to RIG-I or TBK-1 and the ubiquitination status 
assessed by Western blotting with ubiquitin antibody. Decreased ubiquitination level of 
both RIG-I and TBK-1 were observed in cells co-transfected with PCP cells (Fig. 4. 5A 
and 4. 5B), while the total RIG-I and TBK-1 levels were not affected in whole cell lysate. 
These results suggested that PCP may inhibit RIG-I and TBK-1 activation via its 





Fig. 4.4 Inhibition of IRF3 phosphorylation by X domain 
A. Expression of HPX fragment inhibits IRF-3 phosphorylation. HEK293T cells were transfected with 
IRF-3 and empty vector (EV) or HPX plasmids, and then transfected with polyIC (PIC). At 8 h post-
PIC treatment, the cells were harvested for detection of IRF-3 phosphorylation by Western blotting 
with antibody against phosphorylated IRF-3 (pIRF-3). Total IRF-3 and HPX expression were detected 
with IRF-3 and HA antibodies, respectively.  B. Identification of X domain in inhibition of IRF3 
phosphorylation. HEK293-VenusC1-IRF-3 stable cells were transfected with HV, Pro or X domain 















Fig. 4.5 Deubiquitination of RIG-I and TBK-1 by PCP domain 
A. RIG-I deubiquitination by PCP. HEK293T cells were transfected with PCP and RIG-I 
plasmids, and then transfected with polyIC (PIC). At 8 h post-PIC treatment, the cells were 
harvested for immunoprecipitation with RIG-I antibody. Western blotting with antibodies 
against ubiquitin and RIG-I was conducted. Whole cell lysate (WCL) was used to detect 
ubiquitin, RIG-I, PCP and tubulin. B. TBK-1 deubiquitination by PCP. Experiment was 
done similarly as in “A” with the exception of TBK-1 plasmid used. 
Fig. 4.6 HEV replication leads to downregulation of IRF3 phosphorylation 
and deubiquitination of RIG-I and TBK-1 in S10-3 cells.  
A. Reduction of PIC-induced IRF3 phosphorylation in S10-3 cells transfected with HEV RNA 
from pSK-E2-GFP replicon. The cells were treated with PIC to induce IRF3 activation. At 8 h 
post-PIC treatment, the cells were harvested for detection of IRF3 phosphorylation by Western 
blotting with antibody against pIRF3. Total IRF-3, GFP and tubulin were detected too. B. 
Deubiquitination of RIG-I in S10-3 cells with HEV replication. At 8 h post-PIC treatment, the 
cells were harvested for immunoprecipitation with RIG-I antibody. Western blotting with 
antibodies against ubiquitin and RIG-I was conducted. Whole cell lysate (WCL) was used to 
detect ubiquitin, RIG-I, PCP and tubulin. C. Deubiquitination of TBK-1 in S10-3 cells with 





HEV replication in hepatoma cells inhibits IRF3 phosphorylation and ubiquitination of RIG-
I and TBK-1 
 The above results showed that overexpression of X and PCP domains from HEV 
ORF1 in HEK293T cells led to inhibition of IRF3 phosphorylation and RIG-I and TBK-1 
ubiquitination, respectively. We reasoned that the HEV ORF1 product could perform the 
same functions during whole viral infection in hepatoma cells. To test this speculation, 
we employed HEV replicon pSK-E2-GFP. S10-3 cells that were transfected with RNA 
from E2-GFP and cultured for 10 days were stimulated with polyIC for 10 h. Compared 
to the cells without HEV RNA, the cells with E2-GFP replication had much lower 
polyIC-induced IRF3 phosphorylation, while the total IRF3 level had minimum change 
(Fig. 4. 6A). This result was consistent with the findings for X domain expression in 
HEK293 cells.  
In the S10-3 cells transfected with E2-GFP RNA, ubiquitination levels of RIG-I 
and TBK-1 were also examined. IP results showed that both RIG-I and TBK-1 in S10-3 
cells transfected with E2-GFP RNA had lower ubiquitination levels than the control 
without HEV replication (Fig. 4. 6B and 4.6C). Again the results were consistent with the 
observation of PCP overexpression in HEK293T cells. Endogenous RIG-I in S10-3 cells 
was also detectable, and no change in its expression was observed between control cells 
and E2-GFP RNA-transfected cells (Fig. 4. 6B). So was the total cellular ubiquitination 
level in the whole cell lysate. However, endogenous TBK-1 in whole cell lysate of S10-3 
cells was below detection level in the Western blotting, though it was detectable after 





polyIC-induced IFN production by blocking phosphorylation of IRF3 and ubiquitination 
of RIG-I and TBK-1.  
DISCUSSION  
            Type I IFNs, such as IFN-α and β, are critical to innate immunity against viral 
infection and contribute to the modulation of adaptive immunity (390). Viruses have 
developed a variety of strategies to subvert or evade the innate immune response. IRF3, a 
critical transcription factor, is frequently targeted by viruses to interfere with IFN 
induction. VP35 of Ebola virus inhibits IRF3 activation and this inhibition is related to 
the viral virulence (106). PRRSV nsp1β inhibits IRF3 activation (32). Npro of Classical 
swine fever virus induces proteasome-mediated degradation of IRF3 (27, 96). In this 
study, we demonstrated that HEV replication inhibited IFN production.  Furthermore, the 
ORF1 product was responsible for this inhibition. Out of 8 putative domains in HEV 
ORF1 product, the PCP and X domains were demonstrated to inhibit RIG-I mediated 
signaling in different steps. PCP may mediate the deubiquitination of RIG-I and TBK-1, 
while the X domain may inhibit polyIC-induced IRF3 phosphorylation.  
The X domain of HEV is known as a macro domain due to its homology with the 
C-terminal  non-histone domain of histone macroH2A, and such domains have been 
identified in a variety of bacterial, archaeal, and eukaryotic organisms (reviewed in 
reference (103)). Studies of human macro domains indicate they possess a DNA binding 
motif, and are involved in DNA repair, chromatin remodeling and transcriptional 
regulation. Little information about viral macro domains is available. The coronavirus 
macro domains were shown to possess relative poor ADP-ribose 1"-phosphohydrolase 





In our study, the HEV X domain was found to inhibit IRF3 phosphorylation, 
which appears to be a new function for a viral macro domain. However, we were unable 
to detect interaction between X domain with IRF3 or upstream kinase TBK-1 in IP 
experiments (data not shown). Thus, the mechanism that X domain inhibits IRF3 
phosphorylation needs to be further elucidated. In addition, we also found that X domain 
from HEV could bind tightly with chromosomal DNA when overexpressed in HEK293T 
cells (data not shown).  The human macro domains have a DNA binding motif and are 
involved in down-regulation of gene activation, suggesting that HEV X domain could 
potentially regulate host gene expression such as IFN-stimulated genes, which may 
further dampen IFN signaling. However, due to the lack of X antibody and an efficient 
cell culture system for HEV, we do not know whether X domain perform the function 
during HEV replication.   
Another IFN antagonist we identified from HEV ORF1 is the PCP domain, which 
has moderate similarity to protease domain of Rubella virus (179). While the PCP 
domain encoded by Rubella virus has been shown to be responsible for the proteolytic 
processing of its non-structural protein (232), the role of the HEV PCP in proteolytically 
processing the ORF1 product into small subunits has yet to be confirmed. Recently, the 
connection of ubiquitination and activation of IFN induction pathway was defined 
(reviewed in reference (216)). Since cysteine proteases represent a large family of 
deubiquitinases (13), it implies that viral-encoded cysteine proteases could function as 
deubiquitinases to inhibit ubiquitination-dependent activation of host IFN induction 
pathways. Evidence from other viruses shows that viral coded cysteine proteases indeed 





papain-like protease 2 (415) and the leader proteinase of foot-and-mouth disease virus 
(422). 
In a previous report, HEV Met-PCP polyprotein that contains the Met, Y and PCP 
domains was found to act as a deubiquitinase for ubiquitin, SOMO and ISG15-linked 
proteins in a cell-free system (158). However, the Met-PCP was unable to cleave a 
LXGG motif, which should be recognized by cellular or viral PCP. In this study, we 
demonstrate the PCP domain could act as the deubiquitinase for RIG-I and TBK-1 in 
HEK293T cells. In addition, our data indicate HEV replication in S10-3 cells could lead 
to deubiquitination of RIG-I and TBK-1. Since the PCP domain does not contain a Zn-
binding finger, which is required for protease activity (117), our data suggests that the 
PCP deubiquitinase activity does not rely on its protease activity. Another study from the 
foot-and-mouth disease virus also indicated the deubiquitinase activity of viral leader 
protease does not rely on its proteolytic activity (422).  
What is more, SARS virus processes a papain-like cysteine protease that is 
capable of cleaving ubiquitin and ISG15 conjugated proteins and helping virus evade 
from host innate immunity (213, 311). One study demonstrated that targeting the viral 
cysteine protease by virus-specific inhibitor blocks SARS virus replication while not 
affecting cellular deubiquitinases (310). It implies that deubiquitinase function of viral 
PCP could be a potential therapeutic target.  
In conclusion, in this chapter, we identified PCP and X domains of HEV ORF1 
polyprotein are the IFN antagonists and they inhibit RIG-I-mediated signaling in different 








Primera Sequences (5’ to 3’)b Target gene 




H1F3 GCGAATTCAGAACCACTAAGGTTACCGG Cloning of “Y” 
H1R6 CCCTCGAGTTACTGAGCGTAGAACTCCAAC  
H1F4 GCGAATTCTGTAGGCGCTGGCTCTCGGC Cloning of “PCP” 
H1R5 CCCTCGAGTTAGAGATTGTGGCGCTCTGG  








H1F7 GCGAATTCGGCGAAATTGGCCACCAGCG Cloning of “RdRp” 
H1R2 GCGATATCTCATTCCACCCGACACAGAAT  
H1F10 CGCTCGAGCTTTTGATGCCAGTCAGAG Cloning of “HV” 
H1R16 GCGAATTCTAAACAGCATCAACCTCCGAC  
H1F9 GCGAATTCCCTAGTCCAGCCCAGCCCG Cloning of “Pro” 
H1R18 GCGAATTCTAGCGATGCCGGGCCGTCTGG  
H1F8 GCGAATTCCCGGATGGCTCTAAGGTG Cloning of “X” 
H1R13 CCCTCGAGTGCTGTCCGCGCAACATCC  
IRF3-F2 CGGAATTCGGGAACCCCAAAGCCACGGAT
C 
Cloning of IRF3  
IRF3-R2 CCGGTACCTCAGCTCTCCCCAGGGCCCTG  
RIG-I-F1 TTAGGTACCATGACCACCGAGCAGCGAC   Cloning of RIG-I  
RIG-I-F2 GGAGGTACCTCATTTGGACATTTCTGCTG  
a. F: forward primer, R: reverse primer. The “H1” before a primer name indicates the primer 
 is based on sequences of HEV ORF1.  
b. The italicized letters indicate restriction enzyme cleavage sites for cloning.    
 






Chapter 5: Inhibition of Interferon-Activated Signaling by 
Hepatitis E Virus 
ABSTRACT 
Since the initial identification of HEV, lots of effort have been made to study on 
HEV virology and epidemiology. However, the molecular mechanisms for HEV infection 
remain largely unknown. As an invader, HEV faces host innate immune responses, which 
are mainly mediated by type I IFNs and inflammatory cytokines. Our earlier study 
indicates that HEV inhibits host IFN synthesis. Yet it was not known whether HEV is 
able to inhibit downstream IFN-activated JAK/STAT signaling pathway. In this study, 
we demonstrated that HEV replication in hepatoma cells significantly inhibits type I IFN 
signaling and downstream gene expression and that ORF1 product of HEV is responsible 
for this inhibition. Further analysis of the domains of ORF1 product indicates that 
methyltransferase (Met) and ProX domains are able to inhibit IFN-mediated signaling. 
The expression of Met domain appeared to have no effect on IFN-induced STAT1 
phosphorylation. Immunofluoresce assay shows that majority of Met is located in the 
nucleus and the rest as speckles in the cytoplasm. Further analysis will be conducted to 
elucidate the mechanisms of Met and ProX domains in the inhibition of IFN-activated 








HEV has been classified as the sole member of the genus Hepevirus (74). There 
are at least four major genotypes and a single known serotype for HEV strains (105, 252). 
There are three ORFs in the HEV genome (393).  ORF1 encodes a non-structural 
polyprotein that is required for HEV replication. ORF2 encodes the capsid protein of 
HEV virion. ORF3 encodes a small multifunctional protein with a molecular weight of 13 
kDa (vp13).  
As an intruder for the host cell, HEV faces innate immune responses that are 
mainly induced by activation of host pattern recognition receptors.  Activation of pattern 
recognition receptors results in production of type I IFNs and proinflammatory cytokines. 
Type I IFNs, such as IFN-α and β, activate cells via JAK/STAT pathway and are critical 
to innate immunity against viruses (390). Therefore, viruses evolve different strategies to 
evade from IFN-mediated innate immune responses. Hepatitis C virus phosphatase 2A 
and NS5A disrupts STAT1 phosphorylation and suppresses type I IFN signaling (184, 
364). VP24 of Ebola virus antagonizes IFN signaling by binding host KPNA1 protein, 
thereby preventing them from transporting the tyrosine-phosphorylated STAT1 to the 
nucleus (317). The nps1β of PRRSV is able to induce ubiquitin-mediated degradation of 
KPNA1 to inhibit nuclear translocation of ISGF3 complex (284, 424). Dong et al also 
demonstrated that a type III HEV is able to inhibit IFN-α mediated signaling in A549 
cells via blocking STAT1 phosphorylation by vp13(61). However, in our recent 
publication (also Chapter 6 of this thesis) which demonstrated vp13 from type I HEV can 
enhance IFN induction (264).We did not observe any inhibition of JAK/STAT pathway 





signaling.  It is possible that there is strain or genotype difference for vp13 interaction 
with JAK/STAT pathway. Furthermore, it is unknown that what role the other HEV 
proteins play in JAK/STAT1 signaling pathway.  
In this chapter, we found that HEV replication significantly reduced expression of 
ISGs after IFN treatment of hepatoma cells and that HEV ORF1 product is responsible 
for this inhibition. Further analysis indicates that methyltransferase domain and a 
fragment encoding the hypervariable (HV), proline rich (Pro) and X domains from ORF1 
are able to inhibit IFN signaling. Our findings provide valuable information about 







MATERIALS AND METHODS 
Cells, transfection, viruses and chemicals. HEK293T cells, HEK293 cells and 
S10-3 cell were maintained in the same way as described in Chapter 4. Transfections of 
HEK293T, HEK293, and HEK293-ISRE cells with plasmid DNA were conducted in the 
same way as described in the Chapter 4. HEV RNA transfection of S10-3 cells was 
described in the Chapter 4. 
HEK293 cells stably expressing pGL3.0-ISRE were established by transfection of 
the cells with pGL3.0-ISRE and selection under antibiotic G418, towards which the 
resistance gene was provided by VenusC1 empty vector.  The surviving cells were cloned 
by limiting dilution and cell sorting by flow cytometry. Quantification of firefly 
luciferase activity was described in the Chapter 4. 
Plasmids. Cloning of putative ORF1 domains to vector pCAGEN (Addgene 
plasmid# 11160) with HA-tag at N-terminus was described in the Chapter 4. In vitro 
RNA transcription of HEV replicon pSK-E2 and pSK-E2-GFP was described in the 
Chapter 4.  
Western blot analysis. Cells were lysed in the Laemmli sample buffer for SDS-
PAGE and Western blot as described in the Chapter 4. Antibodies against STAT1-Y701 
(Santa Cruz Biotechnology), STAT2 (Santa Cruz Biotechnology), ISG56 (Thermo Fisher 
Scientific, Rockford, IL) and tubulin (Sigma-Aldrich, St. Louis, MO) were used in the 
blotting. The chemiluminescence signal was recorded digitally using a ChemiDoc XRS 
imaging system (Bio-Rad Laboratories, Hercules, CA). Digital signal acquisition and 






HEV replication inhibits ISGs expression induced by IFN-α 
We first transfected the S10-3 heptoma cells with full-length HEV RNAs. Ten 
days after the tansfection, replication of HEV was detected by IFA using chimpanzee 
anti-HEV serum. HEV-GFP replicon was also included in the transfection, and GFP-
positive cells were observed under flouresence microcsopy. To investigate whether HEV 
replication can inhibit IFN-mediated JAK/STAT activation, we treated S10-3 cells with 
human IFN-α2 at the concerntration of 500 U/mL. At 24 hours after the treatment, the 
cells was lyzed for SDS-PAGE and Western blot assay. STAT2 and ISG56 are two ISGs 
that can be upregulated by IFN treatment in a variety of cell lines such as MARC-145 and 
VERO cells (265, 284). In this experiment,  compared with  normal cells treated with the 
IFN, cells with HEV replication had significant lower levels of STAT2 and ISG56 
proteins (Fig.5.1) , indicating an inhibition of the JAK/STAT signaling. Notablely, in the 
cells with HEV-GFP replicon transfection, expression of  STAT2 and ISG56 were also 
inhibited as well. As insetion of GFP in the HEV replicon disrupts expression of HEV 
ORFs 2 and 3 (71), this result indictaes that the ORF1 product was the major player for 
the inhibition of IFN signaling in the hepatoma cells.  
 Fig. 5.1. Inhibition of ISG expression by HEV replication in S10-3 cells. 
IFN-α2 treatment was conducted to stimulate JAK/STAT pathway in normal S10-3 cells, and cells 
with HEV replication. HEV-GFP replicon was included for comparison. At 12 hours after the IFN 





Met domain and ProX domain of HEV ORF1 inhibit IFN signaling  
After finding that the inhibition of IFN signaling was potentially due to the ORF1 
product, we used plasmids constructed in the Chapter 4 that express 6 fragments of ORF1 
polyprotein with HA tag for screening for the IFN antagonist.  Our earlier experience 
with co-transfection of several plasmids suggests that some viral plasmids interfere with 
expression of the other plasmids. The interference leads to difficulty in normalization of 
the transfection efficiency in such a reporter assay. We also observed that endogenous 
expression of proteins is rarely affected by the transfection. To overcome such 
shortcoming of the co-transfection of multiple plasmids in the screening, we create a 
HEK293 cell line with stable expression of an ISRE reporter containing firefly luciferase 
driven by the ISRE promoter. The cells also express Veuns protein driven by a CMV 
promoter for easy selection during the cell cloning and later use. IFN treatment of the 
stable cells can lead to increased luciferase activity while fluorescence reading from the 
Venus protein can be used as an internal control for normalization. We transfected the 
HEK293 ISRE-stable cells with each of the plasmids and treated the cells with IFN at 
500 U/mL 48h after the plasmid transfection. Based on luciferase activity, the Met 
domain and ProX domain demonstrated the strongest inhibition of IFN-stimulation of the 
ISRE promoter (Fig. 5.2). This result indicates the Met domain and ProX fragment of 






































Fig. 5.2. Screening of ORF1 products for potential JAK/STAT 
antagonists. 
HEK293 ISRE-stable cells were transfected with the plasmids of the ORF1 
fragments and then treated with IFN-α2 at the concentration of 500 U/mL. 
At 24 h after the IFN treatment, the cells were harvested for luciferase 
activity assay. Significant differences from EV control (IFN) are denoted by 





Met domain inhibits IFN signaling without affecting STAT1 phosphorylation 
To further confirm our finding that HEV Met domain inhibits IFN-activated 
signaling, we test whether Met domain inhibit the endogenous ISG expression after IFN 
treatment. Just as expected, when Met domain was expressed in HEK293T cells, IFN-
induced expression of ISG56 was dampened in comparison with normal cells (Fig.5.3A). 
This result is consistent with the ISRE reporter assay. 
Activation of ISG expression needs ISGF3 complex binding with ISRE promoter 
in the nucleus. STAT1 phosphorylation is the key step for the ISGF3 complex formation. 
So we tested whether STAT1 phosphorylation was affected by the Met domain. 
HEK293T cells were transfected with Met plasmid and treated with IFN-α 48 h after the 
transfection. Western blotting revealed that Met domain had minimum effect on STAT1 
phosphorylation (Fig.5.3B).  
In addition, we conducted IFA to observe the sub-cellular localization of the Met 
domain by confocal microscopy.  We noticed that majority of the Met protein was 
located in the nucleus, while the rest exists in cytoplasm as speckles (Fig.5.3C). Whether 
the nuclear or cytoplasmic localization of the Met domain relates to its inhibition of 
JAK/STAT pathway needs further investigation. A plausible speculation is that the 
nuclear Met might inhibit ISGF3 interaction with ISRE promoters because the Met 










Fig. 5.3. Met domain inhibits ISG56 expression without affecting 
STAT1 phosphorylation. 
A: Met domain inhibits ISG56 expression. HEK293T cells were transfected 
with pCAGEN empty vector (EV) or pCAGEN-HA-Met for 48 hours, then 
treated with IFN-α2 at 500 U/mL for 24h. Western blotting with ISG56, 
tubulin and HA was conducted. B: HEK293T cells were transfected with 
EV or Met domain for 48 hours, then treated with IFN-α2 at 500 U/mL for 
1h.  C: Met domain is mainly located in the cell nucleus.  HeLa cells were 
transfected with HA-Met plasmid and, 24 h later, fixed and stained with 
anti-HA antibody for confocal microscopy. Nuclear DNA was counter 






In the Chapter 4, HEV replication in hepatoma cells was found to inhibit the 
polyIC induction of type I IFNs. However, as IFNs need to activate the expression of 
ISGs in the cells via JAK/STAT pathway, many viruses develop varieties of strategies to 
block the pathway to dampen the host defense. In a previous study based in genotype III 
HEV, vp13, the product of HEV ORF3, was shown to bind with STAT1 and inhibit 
STAT1 phosphorylation, thus block IFN-α mediated signaling (61). However, our data 
indicate that the HEV-mediated inhibition of IFN signaling was mainly due to the ORF1 
product as pSK-E2-GFP replicon had similar inhibition to the full length pSK-E2 
replicon. The ORF 2 and 3 are truncated in the pSK-E2-GFP. This difference may be due 
to genotypic difference as our study used a genotype I HEV strain. 
In our screening for IFN antagonist from ORF1 product, the Met domain was 
identified as a potential inhibitor in HEK 293 ISRE reporter cell line. Overexpression of 
Met domain in HEK 293T cells resulted in the inhibition of IFN-stimulated ISG56 
expression. However, our data also showed that the Met domain does not inhibit the 
phosphorylation of STAT1, which is the key step for the JAK/STAT pathway. Thus, the 
inhibition step must be somewhere downstream of STAT1 phosphorylation: either 
STAT1 nuclear translocation or its interaction with ISRE promoters.  
Confocal microscopy showed that majority HA-tagged Met domain has a nuclear 
localization. As the Met domain was proposed to cooperate with  HEV helicase domain 
for catalyzing capping of HEV genomic RNA in the cytoplasm (160), it is intriguing that 
majority of Met-domain is located in the nucleus.  It is possibly the Met in cytoplasm as 





(NLS) has been identified from Met domain, the mechanism for Met-domain’s nuclear 
transportation is not known. It is possible that the Met domain possesses a non-classical 
NLS and competes with STAT1 for the KPNA1 for nuclear transportation since 
phosphorylated STAT1 possesses a non-classical NSL to bind to KPNA1 as well. 
In addition to the Met domain, the ProX domain is able to inhibit the IFN- 
induced ISRE activation as well in HEK293-ISRE reporter cells. As ProX fragment 
codes for HV, Pro and X domain, further research is needed to identify the exact domain 
that is responsible for the JAK/STAT inhibition. Among these three domains, it seems 
that the X domain could be the potential inhibitor as it possesses a DNA binding domain 
and was confirmed to play a role in gene silencing and inactivation. On the other hand, 
our results also indicate that X domain is able to bind tightly with chromosome in 
HEK293T cell (data not shown). It is possible that this DNA binding of X domain plays 










The HEV ORF3 encodes a 13-kDa multifunctional protein (vp13), which is 
essential for HEV to establish an infection in animals. The exact role of vp13 in HEV 
infection remains unclear. In this chapter, vp13 was found to enhance interferon 
production induced by polyIC, a synthetic analog of dsRNA. PolyIC treatment induced 
higher level of IFN-β mRNA in HeLa cells stably expressing vp13 than control cells. 
Using a luciferase reporter construct driven by IFN-β promoter, we demonstrated that 
vp13 enhanced RIG-I-dependent luciferase expression. This enhancement was found to 
be because of both increased RIG-I protein level and its activation. The levels of both 
endogenous and exogenous RIG-I were increased by vp13 due to extension of RIG-I 
half-life. Additionally, vp13 interacts with RIG-I N-terminal domain and enhances its 
ubiquitination, which is essential for RIG-I activation. Analysis of vp13 deletion 
constructs suggested that C-terminal domain of vp13 was essential for the enhancement 
of RIG-I signaling. In HEV-infected hepatoma cells, wild type HEV led to a higher level 
of RIG-I and more polyIC-induced IFN-β expression than ORF3-null mutants. Analysis 
of vp13 from four HEV genotypes showed that vp13 from type I and type III strains 
boosted RIG-I signaling while vp13 from type II and IV strains had minimal effect. 







HEV, a single-stranded positive-sense RNA virus, is the sole member of the 
genus Hepevirus in Hepeviridae family (70). The HEV genome is approximately 7.2 kb 
in length and consists of ORFs (393). HEV ORF3 encodes a phosphoprotein with a 
molecular mass of approximately 13 kDa (vp13) (393). A number of studies showed that 
vp13 plays roles in cellular signaling pathways (7) and interacts with microtubules (154). 
Moreover, vp13 is essential for establishment of HEV infection in macaques and pigs 
under experimental conditions (98, 134). ORF3-null mutants of HEV failed to establish a 
productive infection in Rhesus monkeys suggesting an essential role for vp13 in vivo 
(98). These data indicate that vp13 may play an important role in HEV virus-cell 
interactions. Yet the exact role of vp13 in HEV infection remains unknown. It is also not 
known whether vp13 has any effect on host innate immune responses.  
Host PRRs for RNA viruses include RLR pathway and TLR pathway. TLRs that 
can detect viral RNA are TLR3, TLR7, and TLR8 (111). All TLRs except TLR3 signal 
through the adaptor molecule MyD88 (242). TLR3 signals solely via the adaptor TIR-
domain-containing adaptor inducing IFN-β (TRIF) (120). The RLR family of PRRs is 
comprised of RIG-I and MDA5 (164). Both RIG-I and MDA5 signal through adaptor 
IPS-1 (also known as MAVS, Cardif, VISA) on the outer membrane of the mitochondria 
(169). Both RLR and TLR3 can recognize dsRNA of viral genome or the replication 
intermediates of RNA viruses. Activation of RLR and TLR signaling leads to activation 
of two IκB kinase (IKK)-related kinases, TBK1 and IKKɛ, which phosphorylate IRF3 





induction of type I IFNs, which not only leads to an antiviral state in the neighboring 
uninfected cells, but also serve as key regulators to evoke adaptive immune response. 
In this study, vp13 was discovered to enhance interferon expression induced  by 
polyIC, a synthetic analog of dsRNA. vp13 expression led to increased level of RIG-I via 
extension of half-life of the protein. Immunoprecipitation assay indicated that vp13 
interacted with RIG-I N-terminal domain and increased its ubiquitination. In HEV-
infected hepatoma cells, wild type HEV led to higher levels of RIG-I and increased 
expression of polyIC-induced IFN-β compared to ORF3-null HEV mutants. These results 












MATERIALS AND METHODS 
Cells, viruses and replicons. HEK293T cells and S10-3 cell were maintained as 
same as Chapter 4. HeLa were maintained in DMEM-Reduced Serum (DMEM-RS) 
medium supplemented with 3% FBS. Transfection of HeLa, HEK293T, and S10-3 cells 
was described in Chapter 4.  HeLa cells stably expressing vp13 were established by 
transfection of the cells with VenusN1-H3 or VenusC1-vp13  (154) and selecting for 
resistance to G418 (500 µg/ml). Cell cloning was done by limited dilution. PolyIC 
(Invivogen, San Diego, CA) was used to induce interferon production at a concentration 
of 10 µg/ml for direct addition to the cultured cells or at 1 µg/ml for transfection of the 
cells. Avirulent LaSota Newcastle disease virus with the inserted gene of green 
fluorescence protein (NDV-GFP) was used as an indicator of polyIC-induced interferon 
production, as previously described (265). 
Obtaining of Full-length RNAs of HEV, HEV-ORF3-null, HEV-GFP and HEV-
luciferase by in vitro transcription from replicon plasmids pSK-E2, pSK-E2∆ORF3, pSK-
E2-GFP and pE2-Luc (71, 75, 97) were described in Chapter 4. Transfection of S10-3 
cells with RNAs was described in Chapter 4 as well. 
Plasmids. HEV ORF3 plasmids, VenusN1-vp13 and VenusC1-vp13 used in this 
study were reported previously (154). HEV replicons, pSK-E2, pSK-E2-GFP, pE2-Luc 
and ORF3-null pSK-E2 were described previously (71, 75, 97, 98). ORF3 sequences 
from strains of HEV genotype II (GenBank accession# M74506) and IV (accession# 
AB074915) were synthesized (Genscript, Piscataway, NJ) and cloned to XhoI and EcoRI 
sites in the VenusC1 vector as described (154). ORF3 of HEV genotype III isolate 





6.1. ORF3 truncation mutants were constructed using VenusC1 vector with primers listed 
in Table 6.1. 
Full length RIG-I was cloned into KpnI site in pCMV-Flag-MAT-1 vector.  
Construction of Myc-RIG-I(N) (191), MDA5(N) (441), FLAG-TBK1and FLAG-IKKε 
(81) plasmids were described previously. The pCDNA3-TRIF-CFP (82) and pRK5-HA-
Ubiquitin-K63 (209) were obtained from Addgene.  
Immunofluorescence assay (IFA) and live cell fluorescence microscopy. An 
immunofluorescence assay (IFA) was carried out as described previously in Chapter 4 
using chimpanzee antibody against HEV. GFP expression in live cells transfected with 
RNA from HEV replicon containing GFP gene was similarly observed.   
Western blot analysis. Whole cell lysates were analyzed by sodium 
dodecylsulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and Western blotting as 
described previously (154, 455). Antibodies against GFP (Santa Cruz Biotechnology, 
Santa Cruz, CA), FLAG (Sigma, St. Louis, MO), HA (Thermo Fisher Scientific, 
Waltham, MA), Myc (Rockland Immunochemicals, Inc., Gilbertsville, PA), vp13, RIG-I 
(Santa Cruz) and tubulin (Sigma) were used in the blotting. The Recording and 
quantification of chemiluminescence signal were described in Chapter 4. To determine 
RIG-I half-life, cycloheximide (Sigma) was used at a final concentration of 100 µg/ml to 
inhibit protein translation. Cell lysate samples harvested at indicated time points after 
cycloheximide treatment were subjected to Western blotting.  
Reverse transcription and real-time PCR (RT-qPCR). Total RNA RNA 
isolation, DNase treatment and Reverse transcription was conducted as same as described 





described previously. Real-time PCR with SYBR Green, detection for transcripts of 
house-keeping gene RPL32 and quantification of gene expression was conducted as same 
as Chapter 4.  
Immunoprecipitation (IP). IP was conducted as same as Chapter 4. Antibodies 
against Myc or GFP were added to the supernatant. IP with protein G agarose (KPL Inc, 
Gaithersburg, MD) was done following the manufacturer’s instructions. The samples of 
IP with Myc antibody were subjected to Western blotting with vp13 antibody. The 
samples of IP with GFP antibody were subjected to Western blotting with RIG-I antibody.  
For detection of ubiquitinated RIG-I, N-Ethylmaleimide (NEM) (Thermo 
Scientific, Rockford, IL) was included in the lysis buffer at a final concentration of 50 
µM. After lysate clarification, the supernatant was moved to a fresh tube and SDS was 
added to a final concentration of 1%. The supernatant was then boiled for 5 min and 
cooled down on ice for IP with Myc antibody. The IP samples were subjected to Western 
blotting with ubiquitin antibody. 
Luciferase reporter assay. Transfection of HEK293T cells with firefly luciferase 
reporter plasmid of IFN-β promoter, the indicated plasmids and Renilla luciferase vector 
pGL4.74 hRL-TK (Promega) was described in Chapter 4. VenusC1 Empty vectors of 
testing plasmids were included as control. Measurement of Firefly and Renilla luciferase 
assays were described in Chapter 4.  Firefly luciferase levels were normalized with renilla 
expression. Values representing the fold change in luciferase activity compared to control 
cells are shown.  
Statistical analysis.  Statistical analysis between treatment samples, such as IFN-






vp13 enhances polyIC-induced interferon production 
 In our studies of vp13, we established HeLa cells stably expressing vp13 with the 
plasmids encoding vp13 fused to the N- or C-terminal end of GFP, VenusN1-vp13 or 
VenuC1-vp13, respectively (154). HeLa-VenusN1-vp13 was first used in an assay to 
assess the effect of vp13 on polyIC-induction of type I interferons. NDV is sensitive to 
type I IFNs and was used as an indicator of IFN induction. HeLa-VenusN1-vp13 cells 
were inoculated with NDV-GFP 12 h post treatment with polyIC and monitored for the 
expression of GFP. The cell line had a low level VenusN1-vp13 expression that did not 
interfere with observation of NDV-GFP replication. The HeLa-VenusN1-vp13 stable 
cells were expected to have more or similar number of GFP-positive cells than the control 
cells, if vp13 had inhibitory or no effect on IFN induction. However, substantially fewer 
GFP-positive cells were etected in the cells with vp13 expression compared to control 
cells (Fig. 6. 1A). The vp13 expression in cells without polyIC did not affect NDV-GFP 
replication. The result suggested that vp13 enhanced the polyIC-induced IFN production. 
To confirm this observation, we examined the IFN-β transcript levels by RT-
qPCR. HeLa, HeLa-VenusN1-vp13, and HeLa-VenusC1-vp13 stable cells were treated 
with polyIC for 12 h and harvested for RNA isolation. The direct addition of polyIC to 
the cells was supposed to activate the TLR3 signaling pathway to induce IFN production. 
Both HeLa-VenusN1-vp13 and HeLa-VenusC1-vp13 cells had 5.6 and 10.2-fold more 
IFN-β mRNA compared to normal HeLa cells after polyIC direct treatment (Fig. 6. 1B). 
Because polyIC treatment induced higher levels of IFN-β mRNA in HeLa-VenusC1-vp13 






Fig. 6.1 Enhancement of polyIC-induced interferon production by vp13. 
A. NDV-GFP replication reduced in HeLa cells stably expressing vp13 (VenusN1-vp13). The cells 
were treated with polyIC for 12 h and then inoculated with NDV-GFP. The cells were observed 
under fluorescence microscopy 24 h after NDV inoculation. B. Increase of polyIC-induced IFN-β 
mRNA in HeLa cells with vp13 expression detected by RT-qPCR. The HeLa cells stably express 
with VenusN1-vp13 or VenusC1-vp13 and normal HeLa cells were treated with polyIC, which was 
directly added to the cultured cells. Induction folds of IFN-β mRNA level in comparison to non-
treated control cells are shown. Error bars represent standard errors of three repeated experiments. 
Significant differences from control HeLa cells are shown by “**”, which indicates P < 0.01. C. 
Increase of polyIC-induced IFN-β mRNA in HeLa cells with vp13 expression. The HeLa cells 
stably express with VenusC1-vp13 and normal HeLa cells were transfected with polyIC. Relative 
induction folds of IFN-β mRNA levels are shown. D. Detection of Venus-vp13 fusion protein in 
HeLa-vp13 stable cells. N: VenusN1-vp13; C: VenusC1-vp13. The Western blotting was done with 






following experiments. Similarly, VenusC1-vp13 plasmid was used for further analysis 
of the vp13 effect on IFN signaling. To test if vp13 was also able to enhance polyIC-
activated RLR pathway, we transfected the cells with polyIC. IFN-β mRNA level in the 
HeLa-VenusC1-vp13 cells was 3.7-fold higher than HeLa cells after polyIC transfection 
(Fig. 6. 1C). These results indicated that vp13 enhanced polyIC-induced IFN production 
in HeLa cells.   
The vp13 expression in the stable HeLa cells was detected with anti-vp13 
antibody in Western blotting (Fig. 6. 1D). The stable cells with VenusC1-vp13 had higher 
level of vp13 than the cells with VenusN1-vp13, which may be possibly why the polyIC 






Fig. 6.2 vp13 enhances RIG-I-induced IFN-β expression. 
HEK293T cells were co-transfected with IFN-β promoter luciferase reporter, vp13 and one of 
the following stimulator molecules: RIG-I(N), TRIF, MDA5(N), TBK-1 or IKKɛ.  Empty vector 
(EV) of vp13 plasmid was included as a control.  At 24 h after transfection, the cells were 
harvested for luciferase activity assay. Relative folds of the luciferase activity are shown. 
Significant differences in IFN-β promoter activation between vp13 and EV are denoted by  “**”, 





vp13 enhances RIG-I-induced IFN-β expression in HEK293T cells.  
Overexpression of signal molecules from TLR3 and RLR pathways such as RIG-
I, MDA5, TRIF, TBK1 and IKKε lead to the activation of IFN-β promoter (32, 88, 223). 
To find out which signal molecule in the IFN induction pathway was affected by vp13, 
we examined induction of the IFN-β promoter using a luciferase reporter assay. 
HEK293T cells were transfected with RIG-I(N), MDA5(N), TRIF, TBK1 or IKKε along 
with vp13 or empty vector control. Among the molecules tested, IKKε overexpression 
induced the highest luciferase yield to 2808-fold and TBK1 led to the lowest induction to 
10-fold. Compared with empty vector control, the presence of vp13 significantly 
increased luciferase expression in cells transfected with N-terminal RIG-I or TBK1 by 







6.82-fold, respectively (Fig. 6. 2). Co-transfection of vp13 with the other signal 
molecules did not lead to a significant change in luciferase yield. This result suggested 
Fig. 6.3 vp13 induces elevation of endogenous RIG-I protein. 
Western blotting with antibodies against RIG-I, vp13 and tubulin was conducted. A. RIG-I 
protein level is highly elevated in HeLa-vp13 stable cells. Lysate of normal HeLa cells was 
included as a control. EV: empty vector. B. RIG-I protein level is increased in HEK293T cells 
transiently transfected with vp13 plasmid. The cells were harvested at 48 h after the transfection. 
C. RIG-I protein level is increased in S10-3 cells transiently transfected with vp13 plasmid. The 





that vp13 may function at multiple steps within the RIG-I signaling to enhance IFN 
promoter activation. 
vp13 induces elevation of endogenous RIG-I level 
To determine the mechanism that vp13 enhances RIG-I-mediated IFN induction, 
we first tested whether vp13 affected RIG-I expression. While RIG-I was below detection 
level in control HeLa cells, the endogenous RIG-I was detected in immunoblot analysis 
in HeLa-VenusC1-vp13 stable cells (Fig. 6. 3A). Likewise, transient expression of vp13 
in HEK293T cells increased endogenous RIG-I expression to a detectable level (Fig. 6. 
3B).  Similar results were detected in S10-3 cells, a cell line capable of supporting HEV 
replication. The S10-3 cells transiently transfected with VenusC1-vp13 plasmid had 
considerably higher RIG-I level compared to the cells transfected with an empty vector 
(Fig. 6. 3C). These results indicated that vp13 expression led to an elevation in the basal 
level of RIG-I, which was likely one of the reasons for the enhancement of RIG-I-
mediated IFN-β induction.  
vp13 expression extends the half-life of RIG-I 
The increased level of RIG-I in cells with vp13 expression could be due to either 
higher level of transcription and/or translation or extension of the protein half-life.  To 
distinguish between these possibilities, HEK293T cells were transfected with VenusC1-
vp13 or empty vector and RIG-I mRNA levels were assessed by RT-qPCR. Similar levels 
of RIG-I transcript were detected in the presence or absence of vp13 expression (Fig. 6. 















We next assessed the effect of vp13 expression on translation of RIG-I. HEK293T 
cells were transfected with FLAG-RIG-I plasmid since endogenous RIG-I is barely 
detectable by Western blotting. Exogenous RIG-I protein in the cells with vp13 
expression was 2.8-fold higher than the cells transfected with an empty vector (Fig. 6. 
Fig. 6.4 vp13 extends RIG-I half-life in HEK293T cells. 
A. RIG-I mRNA level remains stable in cells with vp13 expression. HEK293T cells were 
transfected with empty vector or vp13 plasmid and harvested 24 h post-transfection. RT-
qPCR was performed to detect RIG-I transcripts. EV: empty vector. B. vp13 induces elevated 
expression of exogenous RIG-I. HEK293T cells were transfected with RIG-I and vp13 
plasmids.  Western blotting with antibodies against FLAG, GFP and tubulin was conducted. 
C. vp13 extends half-life of RIG-I. HEK293T cells were transfected with FLAG-RIG-I and 
vp13 (right panel) or empty vector (left panel). The cells were treated with cycloheximide 24 
h after transfection and harvested at time points indicated above the images. Western blotting 






4B). These results suggest that vp13 is acting at the protein level. We next examined the 
effect of vp13 on the protein stability of RIG-I. HEK293T cells were transfected with 
RIG-I and vp13 or an empty vector and treated with cycloheximide to block protein 
synthesis. The assay showed that RIG-I levels decreased 0.5-fold after 18 h of 
cycloheximide treatment in cells transfected with empty vector but after 30 h treatment in 
cells with vp13 expression (Fig. 6. 4C). The RIG-I half-life was extended from 18 h in 
the cells with empty vector to 30 h in the cells with vp13 expression, indicating that vp13 
extended the half-life of RIG-I.  
vp13 interacts with the RIG-I N-terminal domain and increases its ubiquitination 
RIG-I is composed of two N-terminal caspase recruitment domains (CARDs), a 
central DexD/H box helicase/ATPase domain and a C-terminal regulatory domain (CTD) 
(442). N-terminal CARDs are responsible for binding to the adaptor molecule IPS-1 on 
mitochondria. In resting cells, RIG-I CTD represses the interaction between CARDs of 
RIG-I and IPS-1 (339). As N-terminal CARDs of RIG-I interact with IPS-1 in RLR-
pathway and ubiquitination leads to RIG-I activation , we tested whether vp13 would 
interact with RIG-I(N) or alter the ubiquitination status of RIG-I N-terminal CARD 
domains. First we determined if vp13 increased RIG-I(N) expression in a similar way to 
the full-length RIG-I protein. HEK293T cells were co-transfected with Myc-RIG-I(N) 
and vp13 plasmids. Western blotting result showed that the cells expressing vp13 had 
similar level of RIG-I(N) to the cells with empty vector (Fig. 6. 5A), indicating that vp13 














Next we tested whether vp13 had direct interaction with RIG-I(N). HEK293T 
cells were co-transfected with Myc-RIG-I(N) and vp13 plasmids. IP with Myc antibody 
was conducted to pull down Myc-RIG-I(N) and Western blotting with GFP antibody 
Fig. 6.5 vp13 interacts with RIG-I N-terminal domain and enhances its 
ubiquitination. 
A. vp13 does not enhance expression of RIG-I(N). HEK293T cells were transfected with vp13 
and RIG-I(N) plasmids.  Western blotting with antibodies against Myc, GFP and tubulin was 
conducted. B. Immunoprecipitation (IP) indicates interaction of vp13 with RIG-I(N). HEK293T 
cells were transfected with vp13 and RIG-I(N) plasmids. The upper image shows the presence of 
vp13 in RIG-I(N) IP complex. The second image from top shows the presence of RIG-I(N) in 
vp13 IP complex. The lower two images shows blotting of whole cell lysate (WCL) with 
antibodies against Myc and GFP to detect RIG-I(N) and vp13, respectively. C. Increase of RIG-
I(N) ubiquitination in HEK293T cells with vp13 expression. IP of HEK293T cell lysate was 
done with Myc antibody. The upper image shows the presence of ubiquitin in the IP complex. 
The lower image shows the RIG-I(N) pulled down. Relative level of ubiquitination signal in the 
upper image is shown after normalization with RIG-I. D.  Increase of RIG-I(N) K-63 
ubiquitination in HEK293T cells with vp13 expression. HEK293T cells were transfected with 





showed the presence of vp13 in the RIG-I(N) IP samples (Fig. 6. 5B). Similarly, IP with 
GFP antibody was conducted to pull down GFP-vp13 and Western blotting with Myc 
antibody showed the presence of RIG-I(N) in the vp13 IP samples. The expression of 
RIG-I(N) and vp13 was verified in whole cell lysate (Fig. 6. 5B). These results indicate 
that vp13 is capable of interacting with RIG-I(N). We reasoned that the direct interaction 
of vp13 and RIG-I(N) could induce RIG-I activation. IP was performed to pull down 
RIG-I(N) and then Western blotting with antibody against ubiquitin was conducted. The 
result showed that in the cells with vp13 expression, ubiquitinated RIG-I(N) was 
significantly elevated to 2.7-fold in comparison to the cells transfected with an empty 
vector (Fig. 6. 5C).  These results suggested that vp13 enhanced RIG-I(N) ubiquitination, 
which may lead to an increase of IFN-β promoter activation. 
It is known that lysine 63 (K63)-linked polyubiquitination of RIG-I by ubiquitin 
ligase TRIM25 and Riplet causes RIG-I activation (85, 86, 274). We reasoned that the 
vp13-enhanced ubiquitination of RIG-I should be K63-linked. HEK293T cells were 
transfected with plasmids of vp13, RIG-I(N), and HA-tagged K63-linked ubiquitin (HA-
K63-ubi). IP of RIG-I(N) and Western blotting with antibody against HA were 
conducted. The K63-linked ubiquitination of RIG-I in the cells with vp13 expression 





the presence of vp13 promoted RIG-I activation shown by K63-linked ubiquitination.  
The C-terminal domain of vp13 is sufficient to enhance RIG-I expression and polyIC-
mediated IFN production 
 To determine which domain of vp13 was associated with the enhancement of 
IFN production, we constructed three truncation constructs of vp13: D1, D2 and D3 (Fig. 
6. 6A). D1 and D3 cover N and C-terminal half of vp13, respectively, and D2 carries the 
majority of vp13 with a deletion at C-terminal end. HEK293T cells were co-transfected 
with plasmids of full length RIG-I and full-length vp13 or those three vp13 truncation 
constructs. Compared to empty vector control, RIG-I levels in the cells transfected with 
vp13, D1, D2 and D3 plasmids increased 3.2, 1.4, 1.2 and 2.8-fold, respectively (Fig. 6. 
6B). Full length vp13 and D3 was detected with a vp13-specific antibody that was 
generated with a C-terminal peptide and GFP antibody. The RIG-I level in cells with D3 
was similar to full-length vp13, which indicates that C- terminal vp13 contains the 
domain responsible for the enhancement of polyIC-induced IFN expression. 
To confirm this observation, we conducted an IFN-β reporter assay in HEK293T 
cells. Results showed that the D3 increased IFN-β promoter activation to a level similar 
to that induced by full-length vp13, while D1 and D2 had minimum effect (Fig. 6. 6C). 
This indicated that the C-terminal domain of vp13 enhanced RIG-I-induced IFN 
expression.  
Presence of vp13 in HEV-infected S10-3 cells leads to higher levels of polyIC-induced 
IFN-β expression than ORF3-null mutant 
 The results above showed vp13 enhanced IFN induction. So we assessed whether 





3 cells, a subclone of Huh-7 cells, which support HEV replication (369). The cells were 








from HEV replicon pSK-E2 or pSK-E2-GFP. The GFP insertion in pSK-E2 interrupted 
ORF2 and ORF3 expression, but offered a convenient indicator for direct observation of 
HEV replication. To determine the RIG-I protein level in the S10-3 cells in the presence 
Fig. 6.6. The C-terminal domain of vp13 appears to correlate with enhancement 
of polyIC-induced IFN-β expression 
A. Schematic illustration of cloning vp13 fragments into VemusC vector. The numbers above the lines 
indicate amino acid position in vp13 (aa1-114). B. The C-terminal domain of vp13 correlates with 
RIG-I elevation. HEK293T cells were co-transfected with RIG-I and vp13 truncation plasmids. Empty 
vector (EV) was included as a control. Western blotting with antibodies against RIG-I, GFP, vp13 and 
tubulin was done. D1, D2 and D3 indicate vp13 deletion constructs. The vp13 antibody is against a C-
terminal peptide, and thus does not react with D1 and D2.  C. IFN-β reporter assay. HEK293T cells 
were co-transfected with RIG-I(N), IFN-β reporter and vp13 plasmids. The cells were harvested for 
luciferase activity assay 24 h after transfection. Relative luciferase level is shown in comparison with 
control cells transfected with reporter plasmid and empty vector. Significant differences in IFN-β 





of vp13 expression, Western blotting was conducted. The result showed that endogenous 
RIG-I in the S10-3 cells with pSK-E2 was considerably higher than the cells with pSK-
E2-GFP or pE2-Luc (Fig. 6. 7A). Densitometry analysis showed that the RIG-I level in 
the cells with pSK-E2 was 2.3-fold higher than the cells with pSK-E2-GFP or pE2-Luc. 
Transfection of the cells with polyIC, which was expected to activate RLR pathway, was 
conducted to induce IFN expression. The cells were harvested 12 h after polyIC treatment 
for RNA isolation and RT-qPCR. Result showed that the S10-3 cells transfected with 
pSK-E2 RNA had 1.9-fold higher level of IFN-β transcripts than cells transfected with 
pSK-E2-GFP RNA in response to polyIC transfection (Fig. 6. 7B). The cells not 
transfected with polyIC had very low level of IFN-β transcript, as expected.  
These results suggested that the presence of vp13 in the S10-3 cells enhanced 
polyIC-induced IFN expression. To confirm the observation, we used a ORF3-null HEV 
replicon, pSKE2Δ3, in which a termination codon was introduced to stop ORF3 
expression and therefore, no vp13 expression (98). The vp13-null mutant had similar 
replication rate as wide-type virus in S10-3 cells (72). Compared to the S10-3 cells 
transfected with wild-type pSKE2 replicon, the cells transfected with vp13-null pSKE2Δ3 
mutant had significantly lower levels of IFN-β transcript after polyIC stimulation (Fig. 6. 
7C). IFA with antibody against the capsid protein confirmed similar HEV replication in 
the S10-3 cells transfected with either wild-type or ORF3-null mutant genomic RNAs 
(Fig. 6. 7D).  These data suggest that the presence of vp13 in HEV-infected cells elevates 












Fig. 6.7 Presence of vp13 in HEV-infected S10-3 cells leads to higher IFN-β 
expression induced by polyIC 
A. Elevation of RIG-I level in HEV-infected cells with full-length HEV RNA. S10-3 cells were 
transfected with RNA from pSK-E2, pSK-E2-GFP, and pE2-Luc replicons. Western blotting with 
antibodies against RIG-I, GFP and tubulin was conducted 10 days after the transfection. Relative 
level of RIG-I after normalization with tubulin is shown below the images. Mock-infected cells 
were included for comparison.  B. IFN-β transcript in HEV-infected S-10 cells detected by RT-
qPCR. The cells were transfected with polyIC to induce IFN expression. Induction folds of IFN-β 
mRNA level in comparison to control cells without HEV RNA  and polyIC are shown. Significant 
differences between test sample and control are shown by “*” and “**”, which indicate P < 0.05 
and P < 0.01, respectively.  C. Absence of vp13 in HEV-infected S-10 cells leads to lower IFN-β 
transcript after polyIC stimulation. D. Detection of HEV replication in S10-3 cells. The left panel of 
images shows immunofluorescence assay of the cells transfected with full length HEV genomic 
RNA from pSK-E2 or pSK-E2Δ3. Left images of red fluorescence indicates the presence of HEV 





           Enhancement of IFN induction by vp13 appears to be genotype-specific. 
 HEV genomic sequences are divergent. There are at least four genotypes of HEV across 
the world. The above experiments were done with vp13 from Sar55, a strain of genotype 
I HEV, which can cause acute hepatitis. We wondered whether vp13 from strains of the 
other three genotypes would similarly enhance IFN production. ORF3 from strains of 
genotype II, III and IV were cloned. To determine the vp13 effect on RIG-I(N)-induced 
IFN production, we performed IFN-β promoter reporter assay. HEK293T cells were 
transfected with IFN-β promoter reporter and vp13 plasmids. The result showed that the 
genotype III vp13 enhanced RIG-I(N)-induced luciferase expression by 2.1-fold 
compared with cells with empty vector (Fig. 6. 8A). vp13 from the genotype II and 
genotype IV HEV strains had slightly lower level of luciferase activity than the empty 
vector. vp13 of genotype I enhanced luciferase activity, as expected.  
RIG-I protein levels in HEK293T cells co-transfected with full length RIG-I and 
one of the four vp13 plasmids were determined by Western blotting. Results showed that 
compared to the cells with empty vector, the cells with vp13 of the genotype III strain 
had 2.4-fold higher level RIG-I expression, which was similar to the cells transfected 
with vp13 from the genotype I strain (Fig. 6. 8B). Blotting with a GFP antibody 
confirmed the similar level expression of vp13 from the four genotypes in the cells.  
However, the cells with vp13 from the genotype II and genotype IV HEV strains led to 
minimal changes of RIG-I level. The results indicate that vp13 from the strains of 
















Fig. 6.8 vp13 from HEV genotype I and III enhance IFN induction. 
A. vp13 from strains of HEV genotype I and III induce higher IFN-β promoter expression. HEK293T 
cells were co-transfected with vp13 and IFN-β promoter reporter plasmids for luciferase reporter 
assay. Relative luciferase level is shown. Significant differences from cells transfected with empty 
vector are shown by “*”, which indicate P < 0.05. B. vp13 from strains of HEV genotype I and III 
induce RIG-I elevation. HEK293T cells were co-transfected with vp13 and RIG-I plasmids. Western 
blotting with antibodies against FLAG, GFP and tubulin was conducted. C. Alignment of amino acid 
sequence of vp13 from the four genotypes (Genotype I (GenBank accession # AF444002), genotype 
II (accession# M74506), genotype III (accession# HQ709170), and genotype IV (accession# 





.Amino acid sequence alignment of HEV vp13 of the four genotypes shows there 
are more variations in its C-terminal than N-terminal domain (Fig. 6. 8C). As the C-
terminal domain correlated with the enhancement of IFN expression, the variation in C-
terminal sequence could mean functional divergence. The amino acid sequence identity is 
86% between genotype I and II, 79% between genotype I and III, 78% between genotype 
I and IV. Together, these data shows vp13 enhancement of IFN induction appears to be 







This study demonstrated that HEV vp13 enhances polyIC-induced interferon 
expression by increasing RIG-I protein level, interacting with RIG-I(N) and increasing 
RIG-I(N) ubiquitination. The vp13-mediated elevation of RIG-I protein level is possibly 
due to the extension of RIG-I half-life.  The C-terminal domain of vp13 was found to be 
sufficient for the enhancement of IFN induction. The vp13-mediated enhancement of IFN 
induction was also observed in HEV-infected S10-3 liver cells.   
We observed that polyIC treatment of HeLa-vp13 stable cells induced stronger 
inhibition of NDV-GFP replication than polyIC-treated normal HeLa cells. The result 
indicates that vp13 plays the role in enhancing polyIC-induced antiviral response. Direct 
addition of polyIC to the cultured cells activates TLR3 pathway and transfection of the 
cells activates RLR pathway. In our experiment, the direct addition induced lower IFN-β 
expression than transfection. So we used the transfection method in this study to delineate 
the mechanism of vp13 enhancement of IFN induction. In addition, our results also 
provide potential answers to the vp13 augmentation of polyIC-induced TLR3 pathway: 
the presence of vp13 enhances TBK1-induced IFN-β expression as TLR3 activation 
induces phosphorylation of IRF3 by TBK1.  
Our screening of signal molecules in the IFN induction pathways identified that 
vp13 could enhance IFN induction by RIG-I and TBK1. The vp13-enhanced RIG-I 
signaling was examined in this study. The mechanism of the vp13 enhancement of IFN 
induction via TBK1 is yet unknown. Up-regulating expression of TBK1 by vp13 might 
be a possible reason, but unlikely, because IFN induction by upstream molecules such as 





The mechanism for vp13-mediated enhancement of RIG-I induction of IFN was 
delineated in this study. Elevation of basal level of RIG-I was discovered in HeLa-vp13 
stable cells, and transiently transfected HEK293T and S10-3 cells. The increase of RIG-I 
in S10-3 cells could be more meaningful as they are liver-derived HEV-susceptible cells.  
The up-regulation of RIG-I appears to be mainly because of vp13-mediated 
extension of half-life of the protein. Presence of vp13 extends half-life of exogenous 
RIG-I from 18 h to 30 h. The possible mechanisms for this extension might be inhibition 
of RIG-I degradation by ubiquitin-proteasome pathway or increase of the protein 
translation. The former speculation sounds more reasonable as cycloheximide treatment 
blocks protein translation. The observations that expression of RIG-I(N) was not affected 
by vp13 and that half-life of the full-length RIG-I protein was extended in the presence of 
vp13 is consistent with this speculation.  
The other reason for vp13-ehancement of IFN induction could be that vp13 
interacts with RIG-I(N) and enhances its ubiquitination. RIG-I(N) IP pulled down vp13, 
vice versa, vp13 IP pulled down RIG-I(N). As RIG-I(N) contains the CARD domains to 
interact with IPS-1 to transmit the signal to induce IFN production, the up-regulation of 
RIG-I(N) ubiquitination by vp13 further enhances the signaling. Two ubiquitin ligases 
TRIM25 (85, 86) and Riplet (274) mediates K63-linked polyubiquitination of RIG-I, 
leading to its interaction with IPS-1. This study shows that vp13 increases K63-linked 
RIG-I(N) polyubiquitination. The increase of K63-linked polyubiquitination is consistent 
with the vp13 enhancement of RIG-I(N) activation. As RIG-I CTD interacts with N-
terminal CARDs in resting cells, vp13 is not able to interact with the whole RIG-I 





change when helicase domain of RIG-I protein senses viral RNA (339), vp13 would be 
able to interact with the CARDs and further augment the activation signaling.  
The active domain of vp13 in this function locates in the C-terminal portion of 
this protein, as identified by truncation analysis. The C-terminal vp13 contains proline-
rich sequence that interacts with SH3 domain in cellular proteins (180). The PSAP motif 
of avian HEV was found to play a role in virus release in vivo though not essential for the 
virus infectivity (170). We constructed mutant vp13 with PSAP mutations and our 
preliminary study with the mutants indicates that the PSAP motif appears not correlate 
with the vp13 enhancement of IFN induction (data not shown). Further study is needed to 
identify the active motif involved in the enhancement of IFN induction found in this 
study. Our finding is consistent with the multi-function characteristic of vp13.  
The vp13-mediated enhancement of IFN induction appears to be true in HEV-
infected hepatoma cells, as polyIC induced higher levels of IFN-β mRNA in HEV-
infected S10-3 cells with vp13 expression. The elevation of RIG-I protein level in the 
HEV-infected S10-3 cells expressing vp13 further substantiates the observation, and is 
consistent with the data that vp13 increases RIG-I protein level in stably or transiently 
transfected cells. Compared to the ORF3 –null mutants, in HEV-infected S10-3 cells, the 
presence of vp13 caused a significant increase in IFN-β mRNA level induced by polyIC. 
The small magnitude of change could be due to the low rate of HEV-positive cells and 
virus-mediated inhibition of the IFN induction. We noticed that HEV ORF1 product 
inhibited polyIC-induced IFN production (manuscript submitted). Therefore, it appears to 
be a balance between IFN induction and inhibition, so that the vp13-induced 





enhancement of IFN induction, vp13 also enhances RIG-I mediated NF-κB promoter 
activation and leads to expression of NF-κB activated cytokines in HeLa-vp13 stable 
cells stimulated by polyIC (data not shown). Among the cytokines elevated, some are 
proinflammatory and may contribute to HEV-mediated inflammation and pathogenesis 
during HEV infection. A recent report observed that higher levels of TNF-α, IL-6, IFN-γ 
and TGF-β1, as well as higher HEV viral load were in pregnant women with acute viral 
hepatitis and fulminant hepatic failure(183). 
It is generally expected that a virus would inhibit the interferon induction and 
signaling to gain time for its own replication. Why vp13, a viral protein, enhances RIG-I-
mediated IFN production is an intriguing question. In addition to the possibilities 
explained above, the vp13-mediated enhancement of IFN induction could possibly play a 
role in the context of HEV infection, for example, stages of virus replication. We 
hypothesize that during early stage of HEV infection, ORF1 is more expressed and IFN 
induction is inhibited, and during late stage, viral RNA replication is completed and 
ORF3 expression is increased to promote HEV egress and spreading to other cells.  
Our data also showed vp13-mediated IFN enhancement is different among the 
four HEV genotypes.  vp13 from a genotype III strain is also able to enhance IFN 
induction in our study, but a recent report showed that vp13 from a strain of genotype III 
inhibits IFN-α activated signaling in HEV-stable A549 cells (61).  The vp13 of genotype 
I strain appears to have no such effect on IFN-activated signaling because NDV-GFP 
replication was inhibited in HeLa-vp13 stable cells after polyIC treatment. The 






On the other hand, the finding that vp13 enhances interferon induction would be 
useful in different applications. For example, the C-terminal domain of vp13 can be 
inserted into genomes of attenuated live virus to induce a stronger innate immune 
response for a better protective immunity. The insertion of C-terminal domain of vp13 
into the recombinant virus also makes vp13 act as a marker to differentiate from the wide 
type virus infection.  Further characterization of vp13 and its active domain in this 

























a. F: forward primer, R: reverse primer. The “H3” before a primer name indicates 
the primer is based on sequences of HEV ORF3.  
b. The italicized letters indicate restriction enzyme cleavage sites for cloning.    
Primera Sequences (5’ to 3’)b Target gene 
RIG-I-F1 TTAGGTACCATGACCACCGAGCAG
CGAC   












Cloning of vp13 D2 
H3F8 GCGAATTCATGTTCATCCAACCAAC
CC 
































In this study, we examined the mechanisms of HEV interference with host innate 
immune system, specifically IFN induction and IFN-activated signaling. Interestingly, 
our data indicate that HEV modulates the IFN pathways in both a positive and negative 
way. On the one hand, the macro domain and PCP domain from HEV ORF1 polyprotein 
are able to inhibit host IFN induction via block IRF3 phosphorylation and ubiquitination 
of RIG-I and TBK1, which resulted in inhibition of IFN induction. Moreover, IFN-
activated signaling can be inhibited by Met domain and ProX domain of the ORF1 
product as well. This indicates HEV is able to antagonize host innate immunity to 
facilitate virus replication.  
On the other hand, vp13, the product of HEV ORF3, plays an active role in IFN 
induction that is reverse to the role of ORF1 product described above. Our data indicate 
vp13 is able to elevate RIG-I expression and activation to enhance host IFN induction. 
Although data from this study indicate functions of ORF1 and ORF3 products seems to 
be antagonizing each other, considering temporal  order of ORF1 and ORF3 expression 
in HEV-infected cells, we hypothesize that HEV modulates host innate immune response 
differently at different stages of viral replication.  
In the early stage of HEV replication, it inhibits host innate immune response to 
facilitate its replication. In the middle and late stage of its replication, the capsid protein 
and vp13 are translated from HEV subgenomic RNA, followed by virion packaging and 
egress. During this late stage, innate immune response, specifically, proinflammatory 





injury and virion release. This assumption is corroborated by a recent report that indicates 
that higher cytokine level in HEV-infected pregnant women correlates with fulminant 
liver failure and liver injury. 
The interesting data from this study provide us with more insight on HEV-cell 
interactions and its molecular pathogenesis. The data can also facilitate the development 
of specific antiviral therapeutics against HEV infection, which should benefit HEV-
mediated acute liver injury in immunocompetent individuals or chronic infection in 
immunocompromised patients. Further work is warranted to elucidate the mechanisms of 







In this study, we firstly demonstrated that HEV inhibit host IFN induction via 
PCP and X domain from ORF1 product. Although PCP domain had been identified as 
deubiquitinase for RIG-I and TBK1, it is possible that PCP domain may cause 
deubiquitination for more molecules such as TRAF6 and NEMO to inhibit NF-κB 
mediated cytokine induction. We will test this hypothesis in future works. Also, the 
mechanism of inhibition of IRF3 activation by X domain is not known. Further work will 
elucidate how X domain inhibits the phosphorylation of IRF3 and the essential motif of X 
in this interference.  
On the other hand, we expect X domain may play more roles than inhibition of 
IRF3 activation. We had observed that X domain can bind chromosome tightly when 
expressed in HEK293T. It is possible that X domain may able to regulate a wide range of 
host gene expression and this could be a common function for X domain homologues in 
other viruses. We will examine this speculation in future works as well. 
In the Chapter 5, we demonstrated HEV Met domain and ProX domain from 
ORF1 product inhibit IFN signaling as well. We speculated the Met domain may result in 
promoter methylation which is downstream of STAT1 phosphorylation and nuclear 
translocation to dampen JAK/STAT activated gene expression. On the other hand, as X 
domain is part of the ProX fragment, it is possible that X domain could bind with ISRE 
promoter region to inhibit transcription initiation. These speculations will be examined 
further in future. 
The vp13 of HEV has been demonstrated as a multifunctional protein. In addition 





signaling. Along this line, the detail mechanisms of the interference are not known. 
Further work will be done to figure out how vp13 extends the half-life of RIG-I and what 
the consequence is for the vp13 enhancement of RIG-I signaling in pro-inflammatory 
cytokine induction.   
In addition, vp13 can be explored to enhance vaccine efficacy by increasing 
innate immune response. Currently, we try to insert vp13 into the genome of modified 
live virus (MLV) vaccine strain of PRRSV to see whether vp13 can be utilized to 
enhance vaccine efficiency of the MLV. Taken together, our study generated valuable 
information that can be further explored for studies on HEV pathogenesis and for the 
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